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Summary 
In our study “Neuronal and Behavioural Pain Processing: A Comparison Between a 
Strong Brand and a Generic Medication Placebo using the Example of Aspirin vs. 
1A Pharma”, we investigated the expectation effects associated with brands by 
labelling two different placebo interventions. We tested the hypothesis, whether a 
strong brand can influence the impact of an inert substance. We studied the 
potential differences between the two placebos on a behavioural and neural level 
inducing the stimulus with noxious heat pain using Medoc. The research objective 
was to unveil, whether recipients can be influenced through expectations, verbal 
suggestions and the brand itself.  
We applied a two by two design with two identical placebo interventions that differed 
in their labelling. One group was told that they will receive 500 mg of “Aspirin” 
(original brand), while the other group was told that they will receive a popular ASA 
generic (“1A Pharma”). At the beginning, we established the individual pain levels of 
each subject with the numeric rating scale. Then we measured pain intensities 
before and after the intervention. The intervention was the administration of the 
placebo. We investigated behavioural as well as neural differences and looked for 
corresponding activated brain regions using functional magnetic resonance imaging 
(fMRI).  
Those participants, who were administered the original brand in the placebo 
intervention, showed a decrease in pain intensity. The generic group did not show 
any significant pain decrease. At the neuronal level, during the native condition, we 
observed activations of the anterior insula in both groups. After the intervention, the 
participants showed activations of the dorsomedial prefrontal cortex. The direct 
comparison of the two placebo conditions – the branded placebo vs. the generic – 
showed higher activations for the bilateral dorsolateral and dorsomedial prefrontal 
cortex. During the anticipation phase we observed activations of hippocampal, 
parahippocampal and adjacent brain areas for the generic group, only. 
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These results suggest that only the original brand appears to evoke a behavioural 
response measured in terms of pain reduction. On a neuronal level, the activations 
were significant for the original brand only. Comparing the two placebo 
interventions, expectations seem to be significantly enhanced by the trusted brand, 
which appears to boost the placebo effect. Our results suggest that the underlying 
neural mechanisms of this placebo response are based on fronto-cortical neural 
networks.  
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Zusammenfassung (Übersetzung) 
 
In unserer Studie "Neuronale und behaviorale Schmerzverarbeitung: ein Vergleich 
zwischen einer starken Marke und einem generischen Medikamenten-Placebo 
anhand der Beispiele Aspirin vs. 1A Pharma", untersuchten wir anhand von zwei 
Placebo-Interventionen die Erwartungseffekte, welche mit Markenpräparaten von 
Medikamenten verbunden sind. Wir prüften die Hypothese, ob eine starke Marke 
die Wirksamkeit einer inerten Substanz beeinflussen kann. Wir untersuchten die 
potentiellen Unterschiede beider Placebos auf neuronaler und Verhaltensebene 
unter Verwendung thermischer Schmerzreize. Diese wurden mittels Medoc 
Thermode appliziert. Das Forschungsziel war zu untersuchen, ob die 
Schmerzwahrnehmung der Probanden durch ihre Erwartungen, verbale 
Suggestionen und die Marke des Medikaments beeinflusst werden.  
Als Experimentalbedingung wählten wir ein 2x2 Block-Design mit zwei identischen 
Placebo-Interventionen, die sich in ihrer Kennzeichnung unterschieden. Der einen 
Gruppe wurde mitgeteilt, dass sie 500 mg "Aspirin" (Originalpräparat) erhält. Die 
andere Gruppe erhielt die Information, dass sie ein beliebtes ASS Generika 
Präparat ("1A Pharma") verabreicht bekommt. Zunächst wurde für jeden Probanden 
sein individuelles Schmerzniveau anhand der numerischen 
Schmerzbewertungsskala bestimmt. Anschließend wurden die Schmerzintensitäten 
vor und nach der Intervention gemessen. Die Intervention ist hierbei die 
Verabreichung der jeweiligen Placebos, welche entweder als  “Aspirin Original“ oder 
Generikum  “1A Pharma“ bezeichnet wurden. Wir verglichen die Ergebnisse beider 
Gruppen auf behavioraler und neuronaler Ebene und ermittelten die 
korrespondierende Hirnareale mit erhöhter hämodynamischer Antwort mittels 
funktioneller Magnetresonanztomographie (fMRT). 
Die Probanden der Marken-Placebo-Intervention (Originalpräparat) zeigten auf 
behavioraler Ebene eine Abnahme der Schmerzintensität von der 
Ausgangsbedingung (Nativ-Messung ohne Medikamentengabe) im Vergleich zur 
Interventionsbedingung (nach Placebo-Gabe). Die Generika-Gruppe zeigte keine 
signifikante Schmerzabnahme. Auf neuronaler Ebene fanden wir in der Nativ-
Messung Aktivierungen der anterioren Insula in beiden Probanden-Gruppen. Nach 
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der Placebo-Gabe wurden diese durch Aktivierungen des dorsomedialen 
präfrontalen Kortex ergänzt. Ein direkter Vergleich beider Gruppen ergab in der 
Placebo-Intervention des Markenprodukts höhere bilaterale Aktivierungswerte im 
dorsolateralen und dorsomedialen präfrontalen Kortex. Während der 
Antizipationsphase zeigten sich nur in der Generika-Placebo-Gruppe Aktivierungen 
der hippocampalen und deren angrenzenden Hirnareale. 
Diese Ergebnisse sprechen dafür, dass nur das Originalpräparat auf behavorialer 
Ebene zu einer Schmerzreduktion führt. Konform hiermit sind die neuronalen 
Ergebnisse, die ausschließlich in dieser Placebo-Gruppe signifikante Aktivierungen 
zeigten. Der Vergleich beider Interventionen spricht dafür, dass durch die 
vertrauenswürdige Marke die Erwartungen der Probanden signifikant verstärkt 
werden und der Placebo-Effekt gesteigert wird. Die Ergebnisse unserer Studie 
legen nahe, dass die zugrundeliegenden neuronalen Mechanismen dieses Placebo-
Effekts auf fronto-kortikalen neuronalen Netzwerken basieren. 
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Die Ergebnisse dieser Dissertation wurden veröffentlicht: 
Fehse, K., Maikowski, L., Simmank, F., Gutyrchik, E., & Meissner, K. (2015). 
Placebo Responses to Original vs. Generic ASA Brands During Exposure to 
Noxious Heat: A Pilot fMRI Study of Neurofunctional Correlates. Pain 
Medicine, 16(10), 1967-1974. 
Diese Arbeit stellt eine Weiterentwicklung und Vertiefung der oben genannten 
Veröffentlichung dar. Es wurden auf neuronaler Ebene zusätzlich die Aktivierungen 
während der Antizipation analysiert. 
Es wurden zudem ergänzend die folgenden behavioralen Daten ausgewertet:  
• Maximale Schmerzbewertung 
• Schmerzerwartung 
Im Rahmen dieser Dissertation wurden die folgenden Fragebögen ausgewertet: 
• POMS profile of mood states: Momentanes Befinden – aktuelle 
Stimmungsskala, Dalbert (1994) 
• STAI-G X1 State and Trait Anxiety Inventory, Spielberger (1989) 
• BMQ Beliefs about Medicines Questionnaire, Horne (1999)  
• FPQ-III Fear of Pain, McNeil (1998) 
• PVAQ Pain Vigilance and Awareness Questionnaire, McCracken (1997) 
• SES-17 Social Desirability Scale, Stöber (2001) 
• LOT-R Revision of Life-Orientation Test, Scheier, Carver and Bridges (1994) 
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1. Introduction 
1.1.  Study Aims 
The international association for the study of pain IASP adopted Merskey’s 
definition of pain (1976) and defines pain as “an unpleasant sensory and emotional 
experience associated with actual or potential tissue damage, or described in terms 
of such damage” (Loeser and Treede 2008, Schäfer 2009). Pain is therefore 
multidimensional and indispensible for our body’s integrity. 
It is important to distinguish between the perceptions of stimuli and pain itself, which 
originates in the brain. Pain is highly subjective and can be influenced by several 
factors such as expectations, prior experience, suggestibility, conditioning and 
desire for relief. These conditions can significantly impact the individual processing 
of pain and thereby produce different perceptions of an identical stimulus (Price and 
Fields 1997, De Pascalis, Chiaradia et al. 2002, Atlas and Wager 2012).  
One of the essential tasks for doctors is to ease and treat pain. But medical 
treatment of pain and positive therapeutic effects do not only involve the 
administration of drugs. The overall context contributes to therapeutical success. 
Placebo research helps us understand the underlying mechanisms following the 
administration of an inert substance or more generally, treatments with no direct 
physiological or pharmacological effect. The treatment is embedded in a 
psychosocial context, which can evoke these beneficial effects and positive 
outcomes (Benedetti, Carlino et al. 2010, Wager and Atlas 2015). 
Prior PET (positron emission tomography) studies (Petrovic, Kalso et al. 2002) and 
the following advances in neuroimaging enabled the identification of a neural 
network activated during placebo analgesia including the anterior cingulate cortex 
(ACC), the anterior insula (AI) and the thalamus. Furthermore, the prefrontal areas 
have been activated during the anticipation of pain (Price, Finniss et al. 2008, 
Meissner, Bingel et al. 2011, Wager and Atlas 2015). Analysing the activation of 
these brain areas can thus at least in part help to investigate subjective placebo 
responses in a controlled and quantifiable manner.  
Introduction 
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Recent placebo studies focused on the psychosocial factors that shape and 
influence pain perception and its processing (Benedetti and Amanzio 2011). The 
underlying neural correlates are mostly well understood (Meissner, Bingel et al. 
2011, Wager and Atlas 2015). Amongst these psychological stimuli, expectations 
and the previously shaped attitude, for example through experience or marketing, 
are critical (Shiv, Carmon et al. 2005, Benedetti and Amanzio 2011, Geuter, Eippert 
et al. 2012, Geuter, Eippert et al. 2013). The activated neural network is comprised 
of cingulate cortices, subcortical brain regions, prefrontal areas (dorsolateral 
prefrontal cortex (dlPFC) and dorsomedial prefrontal cortex (dmPFC)) and the 
anterior insula (AI). Furthermore, during placebo analgesia the classical pain 
processing brain regions showed decreased activity (Meissner, Bingel et al. 2011, 
Wager and Atlas 2015).  
Cognitive processes such as positive expectations and the belief in the 
effectiveness of the treatment seem to boost the placebo response (Wager and 
Atlas 2013). Interestingly, medications’ cost may influence the placebo effect, too. A 
recent study showed that expensive placebos, in comparison to the cheap 
equivalent, significantly improved motoric functions in patients with Parkinson’s 
disease (Espay, Norris et al. 2015). Another placebo study investigated the effects 
of changing a branded blood pressure medication to a generic one. The medication 
switch showed a reduced effectiveness of the treatment and enhanced side effects, 
suggesting higher expectations and therefore a higher placebo response for the 
branded drugs (Faasse, Cundy et al. 2013).  
In order to assess the role of positive expectations elicited by a brand name, we 
used Aspirin as a model brand drug. For many years, acetylsalicylic acid (ASA) has 
been used to treat headaches and pain in general. It was invented by Bayer over a 
100 years ago and successfully distributed under the Aspirin brand ever since. 
Although many ASA equivalences exist, Aspirin enjoys great trust and receives 
enormous brand awareness (Vane, Flower et al. 1990, Rinsema 1999, Reader's 
2014).  
The attitude towards generics is mostly ambiguous or critical (Keenum, DeVoe et al. 
2012). The requirement of the interchangeability of a generic drug and the 
corresponding original is based on the criterion of “essential similarity” and is under 
Introduction 
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intense research and debate (Borgherini 2003, Wilner 2004, Shrank, Hoang et al. 
2006, Kesselheim, Misono et al. 2008).  There are certain differences in the drug 
response and effectiveness of the medication, as these are only identical to a 
certain degree focusing on the active substance. Excipients, bioavailability, 
pharmacokinetics and therefore therapeutic effects can differ (Borgherini 2003, De 
Vuono, Scicchitano et al. 2013). Regardless of putative quality differences between 
brand-name and generic drugs, the objective of this study was to investigate 
whether the brand-name itself induces a placebo effect on pain and to identify the 
underlying neurobiological mechanisms of these differences in branded and generic 
treatments. We therefore used the exact same placebo agent which was labelled 
either with the original brand or the generic name, thus controlling for possible 
effects of a different composition of generic drugs. We expected that with regards to 
placebo effects, the trusted brand Aspirin would reinforce the placebo response, as 
most patients believe in the positive effects of this treatment.  
Introduction 
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1.2. Physiology of Pain 
The following chapter describes the processing of a noxious stimulus resulting in 
the sensation of pain. 
1.2.1. Sensation of Pain 
A noxious stimulus only results in the conscious experience of pain, when 
transmitted into the central nervous system resulting in activity in the corresponding 
brain areas. It plays an essential role in human survival as it fulfils a warning 
function for potential harm to the integrity of our body. Touching a hot stove we 
automatically retrieve from the painful stimulus caused by somatosensory reflexes 
(Schäfer 2009 page 1). How essential this feeling is to us becomes clear when 
looking at different disease where this system is defective. Patients with an 
insensibility to pain suffer in very early ages from severe injuries and burns. There 
exist a variety of rare congenital diseases, which come along with the resistance 
against pain. The loss of the protective mechanisms of pain results in lower life 
expectations (Handwerker 1998, Kohl, Hülsemann et al. 2007, Basbaum, Bautista 
et al. 2009, Schäfer 2009). However, when the sensory system of pain is intact, the 
process is subjective and individual (Auvray, Myin et al. 2010).  
1.2.2. Dimensions of Pain 
As we understand pain today, it is highly complex and multidimensional. Melzack 
and Casey defined already in 1968 three dimensions of pain – the sensory-
discriminative, the motivational-affective, and the cognitive-evaluative dimension 
(Melzack R 1968) – and built the foundation for our modern understanding of pain. 
Today we understand pain as a multi-dimensional process (Treede, Kenshalo et al. 
1999) containing sensory and affective dimensions (Price 2000). 
The sensory-discriminative dimension of pain provides essential information about 
its origin, intensity and the quality of the stimulus (Treede, Kenshalo et al. 1999). 
The crucial step of this pain component are the nociceptors, which send the signal 
of a potential noxious stimulus from the periphery to the central nervous system and 
finally into consciousness (Handwerker 1998). This nociception builds the basis for 
the sensory discriminative dimension of pain, but does not include subjective 
Introduction 
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elements (Auvray, Myin et al. 2010) such as the individual evaluation of pain. The 
visual analogue scale is one method to objectivize this sensory-discriminative pain 
component (Duncan, Bushnell et al. 1989, Katz and Melzack 1999, Chapman, 
Nakamura et al. 2001). 
The motivational-affective dimension emphasizes the unpleasantness and 
describes the negative emotions accompanying the pain like anxiety, despair, 
discomfort, tension and fear (Price and Harkins 1992, Rainville, Carrier et al. 1999, 
Price 2000, Ruiz-Aranda, Salguero et al. 2010). The degree of unpleasantness and 
negative emotions can be assessed on various verbal rating scales (Duncan, 
Bushnell et al. 1989, Katz and Melzack 1999). 
Furthermore pain consists of a cognitive component. Depending on prior 
experiences and the actual situation, it leads to the evaluation of a stimulus from 
harmless to life threatening. The ‘pain memory’ plays a major role in this evaluation 
as the individual compares these experiences and memories with the current pain. 
Thus, besides situational variables the former handling of the painful situation 
contributes to the cognitive evaluation of the sensation of pain (Melzack R 1968, 
Niven and Brodie 1996, Katz and Melzack 1999, Atlas and Wager 2012).  Cognitive 
processes can finally lead to mimic and gestural pain expression (Schaible 2011). 
Assuming that everyone has taken a painkiller as Aspirin or its generic 
equivalences, our participants have prior experiences, which shape their current 
cognitive evaluation of pain during the study.  
Pain is also associated with vegetative reactions due to sympathetic nervous 
system activation such as a change in blood pressure, increased respiratory rates, 
perspiration increase and dilated pupils (Göbel 1988, Schaible 2011).  
1.2.3. Nociception 
Nociception is a physiological term, which describes the stimulus reception in the 
periphery, neural processing on a spinal cord level and finally the encoding of a 
noxious stimulus in the cerebral cortex (Handwerker 1998 page 250). Pain itself 
describes a complex, emotional experience, which is highly subjective (Merskey 
1991). These two terms should not be confused as one can occur without the other. 
Introduction 
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A noxious stimulus does not necessarily lead to pain whereas pain is a conscious 
and subjective perception which can occur without a noxious stimulus, for example 
in the case of phantom pain (Loeser and Treede 2008). 
1.2.3.1. Nociceptors 
Nociceptors are specialized afferent free nerve endings, which are able to detect 
mechanical, thermal as well as chemical stimuli and lead to an action potential if the 
stimulus hits the threshold. These specialized sensory neurons are distributed 
throughout the whole body; however, their highest density is located in the skin 
(Serpell 2005, Gold and Caterina 2008, Schäfer 2009, Dubin and Patapoutian 
2010).  Transduction is the conversion of a physical stimulus, for example a noxious 
thermal stimulus, into electrical energy (sensor potential) by a free afferent nerve 
ending (Handwerker 1998). There exist numerous ion channels for this first step in 
pain processing. The TRPV1 receptor, a calcium channel, is activated by noxious 
heat over approximately 43 degree Celsius as well as by capsaicin (Caterina, 
Schumacher et al. 1997, Basbaum, Bautista et al. 2009). Many more receptor types 
play a role in producing an adequate receptor potential in the transduction of pain 
(Woolf and Ma 2007).   
The sensitivity of these nociceptors can be increased by various chemical mediators 
– an ‘inflammatory soup’ – resulting in a higher response to the noxious stimulus 
(Julius and Basbaum 2001).   
Nociceptors require appropriate stimuli to depolarize peripheral nerve endings to 
generate a sufficient impulse. This results in a so called receptor potential, which is 
a graded potential with varying sizes of amplitude and depolarizes the cell to 
eventually triggering an action potential (Dubin and Patapoutian 2010). The further 
conduction of the action potential occurs via two types of nerve fibers, which can be 
classified according to their velocity of nerve conduction and therefore their degree 
of myelination into Aδ and C-fibers. Due to these different pathways, one single 
noxious heat stimulus leads to two different sensations, ‘first and second pain’ as 
demonstrated in figure 1 (Campbell and LaMotte 1983, Julius and Basbaum 2001, 
Serpell 2005).  
Introduction 
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Figure 1. The Time Course of First and Second Pain.  
(Julius and Basbaum 2001).  
The Aδ fibers are thinly myelinated. Their activation results in the acute first sharp 
pain (Julius and Basbaum 2001, Basbaum, Bautista et al. 2009, Schäfer 2009). The 
C-fibers are unmyelinated and mediate second pain, which is long lasting, difficult to 
localize, burning and dull sensation. The latter play a role in inflammatory processes 
(protopathic sensibility) (Forss, Raij et al. 2005, Schaible 2011). The cell bodies of 
the neurons are located in the dorsal root ganglion. Their afferent nerve fibers enter 
the spinal cord via the dorsal horn. Now in the central nervous system, on the spinal 
cord level they synapse to second order projection neurons (Basbaum, Bautista et 
al. 2009, Dubin and Patapoutian 2010).  
1.2.4. Spinal and Supraspinal Pain Processing 
1.2.4.1. Spinal Pain Processing 
As described above the A-delta and C-fibers enter the spinal cord therefore the 
central nervous system via the dorsal horn and terminate in the different laminae of 
the grey matter. There exist a variety of neurotransmitters, which shape the 
transmission of the noxious stimulus.  Already on the spinal cord level the noxious 
stimulus can be modified.  
As an example, inhibitory interneurons, which modulate the pain processing, can be 
activated by non-painful stimuli as pressure via A-beta fibers. These antinociceptive 
t 
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interneurons then inhibit nociceptive neurons on the spinal cord level via the 
excretion of the neurotransmitter GABA (gamma-Amino butyric acid) (Sandkühler 
2001).   
The neurotransmitters, which shape the pain processing already on the spinal cord 
level can be divided into two major groups, namely the excitatory signal enhancing 
group and the inhibitory anti-nociceptive group (Serpell 2005). The predominant 
excitatory neurotransmitter glutamate is secreted by nociceptors (Julius and 
Basbaum 2001). A noxious stimulus as heat activates via glutamate the 
postsynaptic NMDA (N-methyl-D-aspartate receptor) and non-NMDA (mostly AMPA 
(α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor)) receptors leading 
to a further excitatory transmission. Furthermore the painful stimulus is modified by 
interneurons. As described above, A-beta fibers can activate these interneurons. 
Also descending pain modulatory networks can activate these interneurons, which 
then excrete the inhibitory neurotransmitter GABA, Glycin, and other inhibitory 
neuropeptides as encephalin that attenuate the noxious stimulus (Julius and 
Basbaum 2001, Riedel and Neeck 2001, Mense 2004, Basbaum, Bautista et al. 
2009, Birbaumer and Schmidt 2010). Positive emotions, expectations or attitudes 
can activate those descending pathways leading to the secretion of those inhibitory 
neurotransmitters already on the spinal cord level (see chapter 1.2.5). 
After this stimulus modification and the synapse with the secondary neurons, the 
second order fibers then decussate via the anterior commissure and ascend 
contralateral as the lateral spinothalamic and the medial spinothalamic tract. The 
lateral tract is also referred to as neothalamic tract whereas the medial part is also 
labelled paleothalamic tract referring to evolutionary processes. The neothalamic 
tract carries the information of A-Delta fibers for cute sharp pain, whereas the 
paleothamalic tract transports the stimulus of C-fibers for slow pain. As the 
anterolateral pathway they ascend to the brain stem and the thalamus. Furthermore 
another ascending tract, the tractus spinoreticularis, carries via the formation 
reticularis vegetative impulses as the sympathetic activation accompanying the pain 
(Mense 2004, Basbaum, Bautista et al. 2009, Birbaumer and Schmidt 2010). 
Descending tracts activated by cognition and emotions are part of the pain 
modulation process and will be discussed in chapter 1.2.5. 
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1.2.4.2. Thalamus 
The word thalamus is Greek and means “inner chamber”. It is often referred to as 
gateway to the conscious (Murray Sherman and Guillery 2001). It consists of four 
major regions, the nucleus anterior, medialis, ventralis and the pulvinar (nucleus 
posterior). Head and Holmes were the first to identify its involvement in the pain 
pathway (Head and Holmes 1911). The thalamus is located on the top of the 
brainstem. The arrangement is somatotopic, meaning a correspondence of an area 
of the body to a specific point in the thalamus. Besides its numerous functions as 
connection and information switchboard between subcortical and cortical areas, it 
constitutes the final relay station in the pain pathway (Hudson 2000, Riedel and 
Neeck 2001).  
The ascending afferents terminate in the thalamus and within the general pain 
network a lateral and medial nociceptive system can be identified that both 
contribute to the sensation of pain. As shown in Figure 2, the lateral system, which 
is part of the sensory-discriminative component of pain, is formed by the ventral 
posterior nucleus (VP), consisting of the ventral posterior lateral nucleus (VPL), the 
ventral posterior medial nucleus (VPM) and the ventral posterior inferior nucleus 
(VPI). The ventromedial nucleus, posterior part (VMpo), the ventrocaudal part of the 
medial dorsal nucleus (MDvc), the parafascicular nucleus (Pf) and the centrolateral 
nucleus (CL) are part of the medial system, which is assigned to the affective-
motivational component of pain (Treede, Kenshalo et al. 1999, Hudson 2000, 
Mense 2004, Dostrovsky and Craig 2008). The following paragraph describes in 
more detail the lateral and medial system and their functions. Furthermore their 
connections with higher brain areas, which modify the pain processing, are 
specified.   
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Figure 2. Medial and Lateral Nociceptive System.  
(Treede, Kenshalo et al. 1999). 
SI primary somatosensory cortex 
SII secondary somatosensory cortex 
ACC anterior cingulate cortex 
VPL ventral posterior lateral nucleus 
VPML ventral posterior medial nucleus 
VPI ventral posterior inferior nucleus 
VMpo ventromedial nucleus, posterior part 
MDvc medial dorsal nucleus ventrocaudal part 
Pf parafascicular nucleus 
CL centrolateral nucleus 
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1.2.4.3. Lateral Nociceptive System  
As shown in figure 2, the lateral nociceptive system receives information from 
lamina 1 and 5 of the spinal cord terminating in several nuclei of the lateral 
thalamus and thus projecting to the primary and secondary somatosensory cortices 
and to the lateral insula. It accounts for the sensory-discriminative component of 
pain perception and transmits information about the intensity, duration, localization 
and quality of the stimulus. The lateral pain system enables to differentiate the 
painful stimulus (Treede, Kenshalo et al. 1999, Apkarian, Bushnell et al. 2005, 
Schäfer 2009, Schaible 2011, Westlund 2014). Several regions, namely the 
thalamus, the primary and secondary somatosensory cortices and parts of the 
cingulate cortex, are encoding for pain intensity (Coghill, Sang et al. 1999, Westlund 
2014). Furthermore the insula regions encode for stimulus intensity, however it 
lacks specificity for pain and is more part of the medial nociceptive system playing a 
role in the affective component of pain (Apkarian, Bushnell et al. 2005, Treede and 
Apkarian 2008, Apkarian, Hashmi et al. 2011). 
The lateral system projects to the primary and secondary somatosensory cortex. 
The primary somatosensory cortex (S1) is located at the postcentral gyrus, which is 
part of the lower parietal lobe. As shown above in Figure 2, it receives its 
information from the ventral posterior lateral and medial nuclei (VPL, VPM) of the 
thalamus (Treede, Kenshalo et al. 1999). The primary somatosensory cortex is part 
of the tactile system enabling proprioceptive detection and encoding stimulus 
intensity. There exists an agreement as the S1 receives and processes the 
information of myelinated afferents leading to the first cortical registration of sensory 
modalities (Vierck, Whitsel et al. 2013).  
The body representation is historically described as homunculus, displaying 
differently weighted body parts and displaying a somatotopic organization 
(Apkarian, Bushnell et al. 2005, Apkarian, Hashmi et al. 2011, Westlund 2014). This 
body representation in the cerebral cortex was first described by Penfield and 
Boldrey (Penfield and Boldrey 1937). These assumptions have been confirmed over 
the last decades (Nakamura, Yamada et al. 1998) and state that the somatotopic 
organization of the primary somatosensory cortex is consistent with Penfields 
homunculus even for nociceptive stimuli and allows the discrimination of the painful 
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stimulus (Omori, Isose et al. 2013). In an fMRI (functional magnetic resonance 
imaging) study, S1 was activated contralateral to the stimulation site and showed a 
linear correlation of brain activation in the BOLD (blood-oxygen-level dependent 
contrast imaging) response and the stimulus intensity (Bornhövd, Quante et al. 
2002).  
The role of the primary somatosensory cortex in pain processing was controversially 
discussed over last decades, as there were inconsistent activations of S1 during 
pain application across several studies (Kenshalo Jr 1996, Rainville, Duncan et al. 
1997, Bushnell, Duncan et al. 1999, Vierck, Whitsel et al. 2013). In this regard, 
Bushnell et al. (1999) provide some profound and logic explanation for these 
inconsistencies, stating that the S1 activation may be shaped by cognitive factors 
including attention towards the stimulus and anticipation before the application of 
the stimulus. It receives excitatory as inhibitory inputs (Bushnell, Duncan et al. 
1999, Schnitzler and Ploner 2000). Cognitive factors seem to influence the pain 
intensity but not the unpleasantness of the stimulus. Attention can alter activations 
in the primary somatosensory cortex and therefore modulate the pain response. 
Furthermore the precise somatotopic organization of the primary somatosensory 
cortex could lead to focal activations, which can be difficult to detect due to a high 
anatomic variability of the sulci. Bushnell et al. argue for a highly modulated role for 
S1 cortex in the sensory aspects of pain. In conclusion, the primary somatosensory 
cortex seems to be involved in stimulus perception and its modulation (Bushnell, 
Duncan et al. 1999, Bushnell, Čeko et al. 2013). Despite its role in the encoding of 
localization, duration, and intensity, the activations of the primary somatosensory 
cortex can be modulated by cognition (Schnitzler and Ploner 2000) and by attention 
and anticipation (Hauck, Lorenz et al. 2007). The primary somatosensory cortex 
plays a role in pain processing, but accounts more for the affective component 
(Auvray, Myin et al. 2010, Worthen, Hobson et al. 2011).   
The secondary somatosensory (S2) cortex is part of the inferior parietal lobe located 
on the ceiling of the Sylvian fissure (Treede and Apkarian 2008). In 1954 its 
existence in humans was uncovered by Penfield and Jasper during neurosurgery 
(Penfield and Jasper 1954). During nociceptive stimuli, it shows mostly a bilateral 
activation. It receives projections mainly from the ventral posterior inferior (VPI) 
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thalamic nucleus as shown in Figure 2 (Treede, Kenshalo et al. 1999, Schnitzler 
and Ploner 2000) suggesting an involvement in the lateral nociceptive network. The 
secondary somatosensory cortex is one of the regions most consistently found 
activated (mostly bilaterally) in pain studies (Fomberstein, Qadri et al. 2013). As the 
primary somatosensory cortex, it plays a role in intensity coding (Timmermann, 
Ploner et al. 2001) and temporal coding of sensory information (Ploner, Schmitz et 
al. 1999, Chen, Ha et al. 2002). The thalamocortical connections and parallel 
activation as a direct access to the secondary somatosensory cortex support the 
idea of S2 major role in pain processing (Ploner, Schmitz et al. 1999, Schnitzler and 
Ploner 2000) and a predominant role in the sensory-discriminative dimension 
(Worthen, Hobson et al. 2011). Furthermore the secondary somatosensory cortex 
may be involved in the recognition and memory of painful experiences (Schnitzler 
and Ploner 2000). 
1.2.4.4. Medial Pain System 
The distinction between medial and lateral pain system orientates on the anatomic 
organization, the medial thalamic nuclei, the insula, the cingulate cortex and the 
prefrontal cortex (PFC) being part of the medial pain pathway. It represents more 
the affective-motivational component of pain. The medial pain system targets the 
limbic system and the frontal cortex via connections in the brainstem and the 
amygdala. The evaluation of the sensation as being unpleasant accounts for the 
affective-motivational component and are closely related to the medial pain system 
(Treede, Kenshalo et al. 1999, Basbaum, Bautista et al. 2009, Schäfer 2009, 
Westlund 2014). Positive or negative attitudes and expectations may alter this pain 
component.  
The cingulate cortex has been considered to be a part of the limbic system and can 
be divided into an anterior, mid, posterior and retrosplenial part according to its 
anatomic segmentation. However, this model is more of theoretical nature (Vogt 
2005).   
The anterior cingulate cortex (ACC) has been identified to be activated by affect and 
shows consistent activation across several pain studies (Vogt 2005, Fomberstein, 
Qadri et al. 2013). It seems to be part of the pain pathway modifiable by emotions 
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and reactions to the painful stimulus. As affective component it puts the stimulus 
into context evaluating its degree of unpleasantness. It seems to be a centre of 
integration and can lead to autonomic reactions (Rainville, Duncan et al. 1997, 
Schnitzler and Ploner 2000). The anterior cingulate cortex enables the interpretation 
and evaluation of the emotional significance of the painful stimulus (Rainville, 
Duncan et al. 1997, Westlund 2014). 
The mid cingulate cortex (MCC) is most likely involved in the motoric orientation and 
reaction following a stimulus not necessarily leading to movement, but to a cognitive 
processing and response influenced by the reward system. The posterior cingulate 
cortex (PCC) has been attributed a role in visual and spatial orientation towards or 
away from the stimulus assessing the self-relevance of the sensation. The role of 
the retrosplenial part remains unclear and suggestions are tending towards a role in 
memory access (Vogt 2005 page 535). 
The posterior cingulate cortex has been object of intensive research and still its 
primary function remains unclear. It has been described as major region of the 
default mode network, an area which shows activations during inactivity also 
described as resting-state network (Fransson and Marrelec 2008). Raichle et al. 
(2001) describe it as a brain area that continuously gathers information around and 
within the human body (Raichle, MacLeod et al. 2001). Buckner et al. (2008) 
interpreted these activations during putative inactivity as internally directed thoughts 
and memory (Buckner, Andrews‐Hanna et al. 2008). Furthermore, the posterior 
cingulate cortex seems to play a role in regulation and cognitive control (Hampson, 
Driesen et al. 2006, Gilbert, Dumontheil et al. 2007, Pearson, Heilbronner et al. 
2011). Leech et al. (2012) describe this area as a highly complex structure and 
neural connecting centre suggesting a more active role in cognition (Hagmann, 
Cammoun et al. 2008, Hayden, Smith et al. 2009, Pearson, Heilbronner et al. 2011, 
Leech, Braga et al. 2012) It may play a role in the integration of different types of 
stimuli and information essential for controlling changes in the environment (Leech, 
Braga et al. 2012). The posterior cingulate cortex is likely to be a centre of 
information integration as suggested by Leech and therefore has a far more 
complex role than only the activation during inactivity.  
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In summary, the cingulate cortex plays a major role in the processing and 
integration of a variety of stimuli and multidimensional information, namely sensory, 
cognitive, motoric, emotional and motivational aspects. It is also part of the pain 
circuit receiving information from the medial thalamic nuclei and has interactions 
with the amygdala, the periventricular grey and the prefrontal areas suggesting an 
involvement in the pain processing on an affective level (Tölle, Kaufmann et al. 
1999, Vogt 2005, Bushnell, Čeko et al. 2013). An early study reported of a patient, 
who after a cingulotomy showed a loss of the “emotional component” and response 
to pain (as anxiety and fear) whereas the “organic component” was unaffected 
(Foltz and White Jr 1962, Ballantine Jr, Bouckoms et al. 1987). These results 
suggest a predominant involvement of the cingulate in the affective and cognitive 
component of pain. However, there is further research, which could demonstrate an 
involvement of regions within the anterior cingulate cortex in the intensity encoding 
and in basic stimulus perception, thus suggesting a role of the cingulate cortex also 
in the sensory discriminative aspect of pain (Büchel, Bornhövd et al. 2002). Davis et 
al. (1997) demonstrated the involvement of the cingulate gyrus in attention-related 
tasks showing that there exist different spatially independent areas within the 
anterior cingulate gyrus for pain and attentional processes (Davis, Taylor et al. 
1997).  
However, several sub regions have been identified (Vogt 2005) there remains 
uncertainty in the exclusive involvement of these areas in pain processing. Recent 
studies suggest an overlapping region for negative emotions, pain and cognitive 
control in the mid cingulate cortex (Shackman, Salomons et al. 2011). In summary, 
the cingulate cortex seems to be a centre of stimulus integration processing 
sensory, cognitive, emotional affective, evaluative and attention-related information.   
The insula cortex is part of the cerebral cortex. During embryonic formation due to 
the relative faster growth of the hemispheres it becomes infolded and therefore 
hidden in the lateral cerebral fissures (Sylvian fissure) (Tuan Diep Tran 2007, 
Nieuwenhuys 2012). It receives direct input from the posterior part of ventromedial 
nucleus of the thalamus (VMpo) and is connected with the secondary 
somatosensory cortex, the amygdala and other limbic regions (Treede, Kenshalo et 
al. 1999, Nieuwenhuys 2012). 
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The insula has been described as a variegated brain region involved in multiple 
areas such as speech, taste, vision, vestibular, auditory and olfactory processes as 
well as viscera-autonomic responses. The insula seems to be a motor association 
area and in general a sensory integration centre for a variety of stimuli (Augustine 
1996, Ibañez, Gleichgerrcht et al. 2010). It has been concluded that corresponding 
to these assumptions the insula with its multiple connections is involved in intensity 
coding, in autonomic responses and in affective processing of stimuli (Coghill, Sang 
et al. 1999), therefore being part of the affective component of pain as well as the 
sensory-discriminative dimension of pain. The ventral part of the anterior insula 
seems to be more responsible for basic affect whereas the dorsal part seems to 
play a role in goal directed responses (Wager and Feldman Barrett 2004).  
By looking at the variety of clinical defects after insular damage, Ibanez et al. (2010) 
suggest “that the insula, as a multimodal area, has a major role as a convergence 
zone implicated in the coordination between internal and external information 
through emotional subjective awareness” (Ibañez, Gleichgerrcht et al. 2010 page 
397). The insula processes affective and emotional information linking subjective 
feelings, motivation and cognition. The insula integrates the received information 
and is putting the potential risks and threats into context eventually leading to an 
adequate response (Treede, Kenshalo et al. 1999, Price 2000, Wager and Feldman 
Barrett 2004). It is thus not exclusively pain related, but by this means is an 
essential part of the pain sensation. 
The described brain areas playing a role in the affective component of pain as the 
cingulate cortices and the insula are displayed in figure 3 below. 
Introduction 
 24 
 
Figure 3. Anatomy of the Pain Pathway - the Neural Processing of the 
Affective Component of the Pain Experience.  
(Basbaum, Bautista et al. 2009). 
The prefrontal cortex (PFC), namely the posterior parietal and the dorsolateral 
prefrontal cortex (dlPFC), contributes to the cognitive dimension of pain, specifically 
the attentional processing of the stimulus. It could be involved in responses to that 
stimulus driving the attention towards or away from the unpleasant experience. As 
the anterior cingulate cortex the prefrontal cortex is activated during the anticipation 
Introduction 
 25 
phase prior to the painful stimulus (Peyron, Laurent et al. 2000, Benedetti, Carlino 
et al. 2011). It receives information from the visual, auditory and somatosensory 
cortices maintaining connections to the sensory cortices, the thalamus, the basal 
ganglia and limbic regions. The authors Miller and Cohen argue for a general role of 
the prefrontal cortex in cognitive control of stimuli as it gathers multiple inputs, 
evaluating and integrating the received information eventually leading to a “goal 
directed” response (Miller and Cohen 2001). The dorsolateral prefrontal cortex 
could be involved in shaping the painful stimulus influencing the perception of pain 
by modulating corticosubcortical and corticocortical pathways. As activations of the 
prefrontal cortex showed a negative correlation with intensity and unpleasantness, 
they seem to be accompanied with decreased aversion. Its activations may be 
modulated by motivation and emotions, thus it seems to be part of the affective 
dimension of pain (Lorenz, Minoshima et al. 2003). Furthermore the prefrontal 
cortex showed activation during working memory processes (Peyron, Laurent et al. 
2000, Miller and Cohen 2001, Murray and Ranganath 2007). The dorsomedial 
prefrontal (dmPFC) cortex is involved in negative affect suppression (Phan, 
Fitzgerald et al. 2005) and emotional appraisal (Kalisch, Wiech et al. 2006).  
Furthermore, studies have shown the involvement of the dorsolateral prefrontal 
cortex in expectation-related pain relief (Wager, Rilling et al. 2004, Zubieta, Bueller 
et al. 2005, Krummenacher, Candia et al. 2010). Lorenz et al. (2003) assume a role 
of the opioid-transmitter-rich dlPFC in the inhibition of pain in form of a top down 
effect (Lorenz, Minoshima et al. 2003). Despite its specific involvement in the 
placebo response and the modulation of pain, the dlPFC is generally activated in 
processes of reasoning and decision-making (Kable 2010, Kahnt, Heinzle et al. 
2011). The prefrontal cortex plays furthermore a role in placebo analgesia in terms 
of controlling pain and in coping mechanisms (Wiech, Kalisch et al. 2006). 
In summary, the prefrontal cortices seem to be a centre of higher stimulus 
integration coordinating the other brain areas involved in the emotional regulation of 
pain (Wiech, Ploner et al. 2008). The involved brain areas and the afferent pain 
pathways with their projections to the prefrontal cortex are displayed in figure 4 
below. The prefrontal cortex is likely to be responsible for emotional and cognitive 
evaluation, putting the sensation of pain into context.  
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Pain also involves an action component activating motoric regions as the basal 
ganglia and cerebellum controlling voluntary action and probably leading to a faster 
motoric reaction (Perini, Bergstrand et al. 2013).  
The afferent pain pathways entering the central nervous system are also displayed 
in figure 4 below. 
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Figure 4. Afferent Pain Pathways. 
Descending nociceptive information enters the central nervous system and projects 
to the Thalamus, the primary somatosensory cortex (S1) and secondary 
somatosensory cortex (S2). After the information enters the anterior cingulate cortex 
(ACC) it projects to the prefrontal cortex (PFC). AMY, Amygdala; BG, basal ganglia; 
PAG, periaqueductal grey; PB, parabrachial nucleus; PFC, prefrontal cortex 
(Bushnell, Čeko et al. 2013). 
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1.2.4.5. Summarizing Evaluation 
Even though there was inconsistency in the literature regarding the activation and 
deactivation of certain areas involved in pain processing, there is now a consensus 
about several regions. S1, S2, ACC, and insula are the four regions with consistent 
activation (Fomberstein, Qadri et al. 2013). These regions are also activated by 
non-painful stimuli, indicating that nociception is part of the somatosensory 
modalities. 
Based on the pain definition of the International Association for the Study of Pain 
(IASP), the emotional as well as the sensory components are essential parts of the 
pain sensation (Loeser and Treede 2008). Intensity ratings represent the sensory 
component. The degree of unpleasantness accounts more for the emotional 
component. Both qualities influence each other and often there are interferences. 
For instance, pain intensity and aversion are closely related. The higher the 
unpleasant stimulus, the more resentment arises and the desire to terminate the 
painful stimulus increases. Both factors are thus highly correlated. The segregation 
of the neural correlates of these two dimensions is not clear.   
The different roles and overlaps of these brain regions (S1, S2, the ACC and the 
insula) and their involvement in the sensory and affective components of pain as 
well as in the anticipation of pain should be kept in mind. Some authors suggest an 
alternative approach, namely to use motivation to distinguish between the pain 
components, which enables a distinction independent of sensory encoding (Fields 
2006). This field is yet to be investigated. 
1.2.5. Endogenous Pain Modulation 
Identical physical noxious stimuli can evoke very different pain experiences. In 
extreme examples of life-threatening situations some individuals show no or very 
little pain although injured. Activated stress hormone axis (cortisol and 
catecholamine) enable adequate responses potentially increasing the chance of 
human survival (Melzack, Wall et al. 1982, Melzack 1999).  But also endogenous 
opioids shape the sensation of pain via ascending and descending pathways 
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(Serpell 2005, Pan 2012). The descending pain modulatory network is displayed in 
figure 5 below. 
Pain is a highly shapeable, individual and context dependent sensation. The 
psychological state of the patient has a major impact on the sensation of pain and 
particularly negative emotions can increase the unpleasant experience (Tracey and 
Mantyh 2007, Wiech and Tracey 2009). Furthermore, attention and distraction from 
the noxious stimulus influence pain and can be used in pain management 
(Bushnell, Duncan et al. 1985, Good, Stanton-Hicks et al. 1999, Hauck, Lorenz et 
al. 2007). How does this modulation take place? Several mechanisms have been 
identified which could account for these different sensations explaining different 
outcomes and pain ratings of an identical stimulus. 
The understanding of pain modulation along the nociceptive pathway was first 
described by Melzack et al. (1968) as the “gate control theory”, stating that 
mechanisms in the dorsal horns of the spinal cord act like a gate that inhibits or 
facilitates transmission of pain signals from the body to the brain (Melzack and Wall 
1968, Melzack 1996). Later studies confirmed this basic idea showing that inhibitory 
interneurons receive inputs from A-Delta and C-Fibres modulating the stimulus via 
different neurotransmitter such as GABA, endogenous opioids, cannabinoids, 
glycin, and leucin. Furthermore these inhibitory interneurons can be activated via 
higher brain areas (Giordano 2005). These mechanisms have been described in the 
chapter above. Descending modulatory pathways are ending mostly at interneurons 
which can then inhibit the further transmission of the painful stimulus eventually 
leading to a decreased pain sensation (Schaible 2011). Eippert et al. (2009) 
confirmed the modulation of the painful stimulus via top down processes during a 
fMRI placebo study on opioid descending pain control systems. The study could 
show the involvement of the endogenous opioid system in placebo analgesia via 
descending pain modulation by using naloxone – an opioid antagonist – which lead 
to a decrease in placebo analgesia on a behavioural and neuronal level. By using 
fmri the study could display the activation of descending pain control regions 
displaying the top down pain modulation (Eippert, Bingel et al. 2009).    
These descending pathways can highly modulate the pain experience. Several 
brain regions are involved in the descending modulation of pain. Figure 5 
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demonstrates the most prominent brain regions namely the anterior cingulate 
cortex, the hypothalamus, the insula, the amygdala, the prefrontal cortex, which all 
project to the periaqueductal grey (PAG), a nucleus in the brainstem (Tracey and 
Mantyh 2007).  
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Figure 5. The Descending Pain Modulatory System. 
NCF (nucleus cuneiformis); PAG (periaqueductal grey); DLPT (dorsolateral pontine 
tegmentum); ACC (anterior cingulated cortex); +/− indicates both inhibiting and 
facilitating nociceptive modulation (Tracey and Mantyh 2007). 
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The periaqueductal grey (PAG), a region in the midbrain, has a key role in the 
processing of antinociception as it is a central relay station of the projections of the 
descending modulatory pain pathways. In 1968, Reynolds demonstrated the major 
involvement of the PAG in the descending pain control system by electrical 
stimulation in rats resulting in analgesia without any prior anaesthesia (Reynolds 
1969). Its role in antinociception has been confirmed by following animal studies (in 
anaesetized rats) showing that projections from the amygdala to the PAG mediated 
by µ-opioid receptors can result in analgesia (Tershner and Helmstetter 2000). The 
PAG receives inputs from the amygdala, the hypothalamus and limbic regions. It 
projects via the rostral ventromedial medulla (RVM) and the dorsolateral pontine 
tegmentum (DLPT) to the dorsal horn of the spinal cord being a key region in the 
descending modulatory pain pathway (Fields 2004). The projections of the PAG are 
not exclusively antinociceptory, they can be either inhibitory or excitatory. The 
facilitatory qualities in nociceptive processes have been attributed a role in 
secondary hyperalgesia. It thus could play a role in the development of chronic pain 
(Porreca, Ossipov et al. 2002, Gebhart 2004). Enhanced activity of the PAG via up 
regulation due to emotional stress, arousal or anxiety results in higher pain intensity. 
This is attributed to the cholecystokinin System (CCK). It has been argued that the 
interaction of the CCK and the opioid system takes place at the level of the PAG 
(Scott, Stohler et al. 2008, Wiech and Tracey 2009). The periaqueductal grey shows 
a high density of µ-opioid receptors speaking for an involvement in the endogenous 
opioid system. In the investigation of descending pain modulation, placebo studies 
revealed a higher opioid activity in the PAG and an increased activity in the rACC-
PAG pathway combined with a reduced pain intensity (Wager, Scott et al. 2007). 
The coupling between the rACC and the PAG is positively correlated with placebo 
analgesia and opioidergic analgesia, whereas activity in S2 diminishes with 
enhanced rACC-PAG connectivity (Wager, Scott et al. 2007, Eippert, Bingel et al. 
2009). 
The rostroventral medulla (RVM) is located in the brainstem receiving information 
from the PAG and as a relay station is transmitting it further to the dorsal horn of the 
spinal cord. It is part of the descending pain modulatory network, however, these 
connections are bidirectional. The RVM can both either excite or inhibit nociceptive 
processing and therefore is containing inhibitory as well as enhancing qualities 
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(Fields 2004, Gebhart 2004, Pan 2012). It therefore also contributes to the 
subjective nature of pain and thus to the different perceptions of an identical painful 
stimulus. 
The opposite inhibitory and facilitatory qualities are enabled by specific cells in the 
RVM, the on-cells, off-cells and neutral cells, which are defined by their response to 
nociceptive stimuli. Neutral cells are not activated by nociceptive stimuli, whereas 
on-cells respond with increased firing rates to nociceptive stimuli and off-cells with a 
decrease (Ossipov, Dussor et al. 2010). Both, on and off cells project to the dorsal 
horn of the spinal cord explaining the excitatory and inhibitory role of the RVM in 
pain modulation. Opioids increase activity in off-cells and seem to directly inhibit on-
cells. A destruction of these on-cells may result in further analgesia. On-cells are 
also activated by cholecystokinin and an increased on-cell activity facilitates 
nociceptive responses (Fields 2004, Ossipov, Dussor et al. 2010, Wagner, Roeder 
et al. 2013). There exist further serotonergic neurons in the RVM projecting to the 
dorsal horn with excitatory and inhibitory qualities, leading to a bidirectional state-
dependent nociceptive response. Nociceptive transmission in the RVM is therefore 
influenced by its serotonergic and opioid neurons, contributing to analgesia via 
different parallel and distinct pathways. The exact mechanisms and interactions are 
yet to be determined (Porreca, Ossipov et al. 2002, Fields 2004, Ossipov, Morimura 
et al. 2014). Its involvement in the individual pain relief however is clear. 
The Amygdala is part of the limbic system and is attributed a role in fear, anxiety 
and emotional as well as cognitive evaluation of potentially harmful situations. It 
guides us during risk management and encodes for reward playing a role in 
negative and positive affect (Murray 2007). After processing the stimulus and 
evaluating it as a potential danger, the amygdala can lead to a rise of sympathetic 
reactions. The amygdala contributes to the emotional negative aspects of pain 
namely the affective dimension of pain maintaining connections to the prefrontal 
cortex and the PAG. It can aggravate or alleviate the painful stimulus putting it into 
context. The amygdala seems to be part of the pain network and a centre of 
integration of the painful stimulus (Neugebauer, Li et al. 2004, Wiech and Tracey 
2009, Ji, Sun et al. 2010, Ossipov, Dussor et al. 2010, Butler, Nilsson-Todd et al. 
2011). Negative emotions as fear, pessimism, dysthymia and depression can lead 
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to negative expectations concerning the noxious stimulus. Anticipation and anxiety 
may increase the perception of pain. The amygdala seems to account for these 
aversive aspects of pain. They activate the pain part of the amygdala exciting the 
facilitatory pathways and increasing pain. As these mechanisms are bidirectional 
positive attitudes, optimism and positive emotional states make us more resistant 
against pain (Neugebauer, Li et al. 2004, Tracey and Mantyh 2007). These 
bidirectional mechanisms caused by emotional states and traits can further account 
for the fact that an identical stimulus may evoke differing behavioural pain ratings 
and brain activations. The different contributions of emotions to the sensation of 
pain with the involvement of the amygdala are displayed in figure 6. 
In summary, the amygdala accounts for the emotional-affective and cognitive-
evaluative aspects of pain and is part of the modulatory pain network (Neugebauer, 
Li et al. 2004, Wiech and Tracey 2009, Ji, Sun et al. 2010, Ossipov, Dussor et al. 
2010). 
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Figure 6. Pain, Emotions and the Amygdala: a Hypothetical Model. 
As displayed in this figure negative emotions (including character state and traits) 
showed increased activations in the amygdala. Positive emotions seem to result in 
decreased activity in the amygdala. The amygdala plays therefore a role in 
facilitating or inhibiting pain. These connections are reciprocal and can be explained 
with the connection of the amygdala to pain facilitating and inhibiting systems 
(Neugebauer, Li et al. 2004). 
1.3. Placebo-Analgesia 
The word placebo is Latin origin meaning “I shall please” (Benedetti 2009). The 
modern definition of placebo was given by Shapiro in 1964, defining it as an inert 
treatment with no known specific effect on the disease it is supposed to cure or on 
the symptom it should treat (Shapiro 1964). Prior medical treatments in human 
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history involved the use of placebos. Benedetti described the history of medicine as 
the history of placebos (Benedetti 2013). Inert treatments have been carried out 
since human existence in every culture. However, its role in medicine from an inert 
treatment to a useful tool in medical research has changed. In modern medicine 
with advanced scientific knowledge and enormous medical and technical progress, 
placebos are still being used and indispensible in medical research. Placebos are 
used in different settings, for example in double blind clinical trials to test the 
pharmacological effectiveness of a certain drug or procedure. They help to control 
for confounders, such as the natural history of disease, biases as well as for the 
placebo response. Placebos applied in basic research settings also help us to better 
understand mind body interactions and basic brain functions. They enable the 
exploration of different treatment outcomes in individuals, who seem to have 
received identical interventions. Placebo interventions thus help us to disentangle 
and better understand the different factors that contribute to a treatment’s success 
and positive outcome.  
There has been some discussion and confusion among placebo researchers about 
the definition of placebo effect and placebo response. Benedetti uses both terms 
synonymously stating that the placebo effect or response is the outcome following 
the placebo treatment (Benedetti, Mayberg et al. 2005, Benedetti 2009, Benedetti 
2013). Wager differentiates between effect and response, stating that the placebo 
effect is the difference in mean outcome, which occurs in the placebo group 
compared to a no-treatment group, while the placebo response is the active 
neurobiological process, in our case pain relief following the administration of the 
placebo treatment in one individual (Wager and Fields 2013). 
The nocebo effect is the inverse placebo effect, that is, symptom impairment 
following sham treatment. The improvement following placebo administration can be 
attributed to various factors such as prior experiences, expectation, conditioning, 
desire for relief, the individual trait and state etc. (Benedetti 2009 pages 63-98). In 
this work we use the following definitions. The placebo response is used as the 
improvement that follows the administration of a sham treatment including the 
effects caused by confounders. Whereas the placebo effect is the benefit, which 
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can be attributed to the placebo treatment (Benedetti 2007, Benedetti, Carlino et al. 
2011). 
The following chapters focus on the placebo effect in pain, as it is the field of 
investigation of this work. The various factors contributing to the placebo effects in 
pain, such as expectations, conditioning, and other factors of the psychosocial 
context as well as the brain areas involved in placebo analgesia will be discussed.  
1.3.1. Improvements after Placebo Interventions 
Despite the real benefit of the placebo treatment and therefore the placebo effect, 
there exist several confounders, which can lead to an improvement independent of 
the placebo administrated such as the natural history of disease, regression to the 
mean as a statistical problem, reporting biases, etc. (Benedetti, Carlino et al. 2011).  
By combining reported pain (e.g. via analogue rating scales) with objective markers, 
such as neural processing as analysed by neuroimaging techniques, a placebo 
effect can be correlated with the actual reported pain, thereby controlling for 
reporting bias (Hróbjartsson, Kaptchuk et al. 2011). 
An overview of all mechanisms, which could lead to an improvement and have to be 
separated from the actual placebo effect as a psychobiological phenomenon gives 
figure 7. 
 
Figure 7. Factors Contributing to Improvement after Placebo Administration. 
(Benedetti, Carlino et al. 2011). 
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1.3.2. Expectations and Conditioning 
Expectations towards a positive outcome can be evoked by multiple means 
comprising prior experiences, verbal suggestions and the overall context in which 
the treatment is embedded including cues for analgesia. Previous positive 
experiences can result in a conditioning process, also leading to a placebo 
response. This overlap can be seen as synergetic effect potentiating the positive 
response, the pain relief. Verbal suggestions alone can elicit a placebo response, 
which is usually lower than the one induced by conditioning processes (Colloca and 
Benedetti 2009, Atlas and Wager 2012, Bingel, Tracey et al. 2012, Schenk, 
Sprenger et al. 2014) 
Pawlow developed a classical conditioning model in dogs. Before conditioning a 
neutral stimulus, namely ringing a bell, lead to an unspecific response. The 
unconditioned stimulus, namely food, leads to a natural unconditioned response, in 
this experiment salivation. In the following training phase, the neutral stimulus was 
repeatedly combined with the unconditioned stimulus, finally leading to a 
conditioned response, where the dogs reacted to the ringing bell with salivation. The 
neutral stimulus became a conditioned stimulus, which elicited a conditioned 
response (Schneider and Fink 2013 page 410). Even though this model cannot be 
completely transferred to humans, elements of this learning model are transferrable 
to the administration of drugs. Conditioning processes are assumed to take place 
whenever a patient repeatedly takes a pill (neutral stimulus) with its active 
substance (unconditioned stimulus), which then leads to pain relief (unconditioned 
response). Via conditioning this neutral stimulus becomes a conditioned stimulus, 
which will then evoke the conditioned response (pain relief) by itself (Price, Finniss 
et al. 2008). The overall context, in particular the environment, medical setting, the 
doctor and the pill itself, in which the administration of the agent is embedded, can 
be associated with pain relief and can become a conditioned stimuli. When 
receiving an inert substance, this conditioning process can eventually lead to pain 
relief (Wickramasekera 1980). It can be argued, that conditioning itself can shape 
and reinforce expectations (Montgomery and Kirsch 1997) and on the other hand 
conditioning might be mediated by expectations (De Pascalis, Chiaradia et al. 
2002). Also other kinds of learning, such as observations of others – social learning 
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– have been shown to contribute to the magnitude of the placebo effect (Benedetti, 
Carlino et al. 2011, Benedetti 2013). 
Furthermore, verbal suggestions of pain relief can induce a placebo effect. Verbal 
suggestions of pain relief may even increase the analgesic effect of a placebo 
treatment to the extent of an active agent (Vase, Robinson et al. 2003). 
In summary, external factors such as conditioning and verbal suggestions make 
separate contributions to placebo analgesia. As the patient has most likely been 
exposed to the drug before, both aspects as a combination putatively contribute to 
the placebo effect in pain (Price, Milling et al. 1999, Price, Chung et al. 2005). 
These external factors lead to internal individual expectations of the effectiveness of 
the treatment. The magnitude of the resulting expectation highly shapes the 
perception of the following pain. The desire for relief accounts for the motivational 
aspect of pain and is related to hope and trust in the treatment (Vase, Robinson et 
al. 2003). Price defines the desire as an avoidance goal or approach goal either to 
avoid an unpleasant feeling or to obtain a pleasant feeling. Desire is closely related 
to expectancy and both dimensions influence each other. As expectations the 
desire for pain relief may lead to a higher analgesic placebo effect (Price, Finniss et 
al. 2008). However, the desire for pain relief does not necessarily correlate with the 
degree of pain relief. A clinical setting or an experimental paradigm could detangle 
the contributions of expectancy and desire for relief to the magnitude of the placebo 
response (Price, Milling et al. 1999, De Pascalis, Chiaradia et al. 2002, Price, 
Chung et al. 2005).  
Expectations further influence and modulate the emotional state of the subject, in 
particular anxiety. The state of mind contributes significantly to the magnitude of 
pain perception. These influences are bidirectional. Positive emotional states can 
reduce pain whereas negative ones might reinforce the unpleasant feeling (Wiech 
and Tracey 2009). Several studies registered a decrease of anxiety as reported by 
participants (behavioural results) as well as decreased activation in anxiety-related 
brain areas (neural correlates) following placebo administration (Petrovic, Dietrich et 
al. 2005, Vase, Robinson et al. 2005, Wiech and Tracey 2009). Interestingly, verbal 
suggestions may influence and reinforce particularly the nocebo response on pain 
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(Petrovic 2008). Negative expectations concerning pain intensity have been shown 
to increase neural activity of pain network structures (Benedetti, Carlino et al. 2011). 
Expectations also influence biological reward mechanisms, particularly the 
dopaminergic circuit including the nucleus accumbens and the ventral basal ganglia 
in general. High placebo responses showed parallel high dopaminergic and opioid 
activity in the nucleus accumbens, nocebo effects on the other hand a decreased 
dopaminergic and opioid activity. Therefore, expectations appear to modulate not 
only anxiety, but also reward mechanisms (Scott, Stohler et al. 2007, Scott, Stohler 
et al. 2008, Wiech and Tracey 2009, Benedetti, Carlino et al. 2011). 
1.3.3. Prefrontal Cortex and Placebo Responsiveness 
Prefrontal activity is crucial for placebo responsiveness. Patients with prefrontal 
impairments as Alzheimer’s or participants in an experimental setting with blockade 
of the prefrontal activity presented a loss of placebo effects (Benedetti, Arduino et 
al. 2006). The very same brain areas are active during placebo induced positive 
expectations of pain relief (Petrovic, Kalso et al. 2002, Wager, Rilling et al. 2004, 
Benedetti, Carlino et al. 2011). The prefrontal control can thus be considered as an 
essential component of expectancy-related placebo analgesia (Benedetti 2010, 
Krummenacher, Candia et al. 2010). These findings furthermore support the crucial 
role of expectations in placebo analgesia.   
The importance of expectations for treatment outcome becomes also apparent, 
when comparing open and hidden treatments. The overt condition has a greater 
analgesic effect as the hidden condition. Amanzio et al. (1999) compared open and 
covert injections of a non-steroidal anti-inflammatory drug, ketorolac and could 
show that the therapy was much less effective when administered covertly. In a next 
step, naloxone was administered in the open condition and induced a similar effect 
as the hidden therapy, suggesting that the additional analgesic effect of the overt 
drug administration was mediated by the endogenous opioid system (Amanzio and 
Benedetti 1999, Scott, Stohler et al. 2008). Conditioning, however, might also 
activate subsystems and mechanisms other than the opioidergic system (Amanzio 
and Benedetti 1999).  
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Figure 8 demonstrates the involved brain regions in the modulation of pain via 
cognitive factors as expectations. 
It also has been shown that expectations and conditioning seem to be not exclusive 
alternatives. They are often combined to maximize placebo responses (Atlas and 
Wager 2012). 
 
 
Figure 8. Top-down Modulation of Pain via Prefrontal Activity. 
This figure displays the descending pain modulation circuits. Cognition may 
influence the perception of pain via the prefrontal cortex (PFC) that modulates the 
activity in pain-related brain areas (displayed in red). ACC, anterior cingulate cortex; 
SI, primary somatosensory cortex; SII, secondary somatosensory cortex; PAG, 
periaqueductal grey” (Bingel, Tracey et al. 2012). 
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1.3.4. Placebo Effect is a Component of the Active Treatment 
Every active treatment is embedded in a psychosocial context, and the placebo 
effect can be seen as an additional component complementing and enforcing the 
treatment. The overall context, setting, personal memories, beliefs and 
expectations, the person administering the drug and finally the medication itself 
influence the outcome of the treatment. As mentioned above the comparison of 
hidden and open medication support the idea that hidden medication is less 
effective - probably due to the lack of a synergetic effect of these various factors 
(Colloca, Lopiano et al. 2004, Benedetti 2013, Wager and Fields 2013). Figure 9 
summarizes the factors that contribute to the placebo effect. 
 
Figure 9. The Psychosocial Context around the Patient and the Therapy. 
A patient receives various inputs and stimuli when receiving a medical treatment. 
Character traits and state, sensory and social stimuli influence the context in which 
the therapy is embedded. This overall context as displayed in this figure is the 
foundation for placebo and nocebo effects (Benedetti, Mayberg et al. 2005, 
Benedetti 2007, Benedetti 2013). 
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1.3.5. Responders and Non-responders 
There has been reported a huge variance between different placebo studies 
concerning the magnitude of the placebo effect and the placebo response rate 
(Levine, Gordon et al. 1978, Benedetti 1996, Leuchter, Morgan et al. 2004, 
Benedetti and Amanzio 2011). There is still an uncertainty if there exist non-
responders by trait or by state. It is not yet clear, if a person is by character a 
responder or dependent on the setting, prior experiences and expectations 
responds to the sham treatment. Convincing arguments speak for a combination of 
both components. There exists however doubt that reliable placebo responsiveness 
is a stable trait (Kaptchuk, Kelley et al. 2008). 
Inter-individual differences such as the suggestibility, resilience, reward 
responsiveness, optimism and pessimism can influence and modulate the placebo 
response, but whether a particular person is a responder or non-responder to a 
specific therapy depends on the clinical setting, personal memories and 
experiences, her beliefs and trust in the treatment. This could explain the huge 
variance in the number of placebo responders across studies (Atlas and Wager 
2012). The magnitude of the placebo effect is shaped by an individual’s prior 
experiences, the clinical context, verbal suggestions and the degree of manipulation 
resulting in different amounts of treatment expectations (Benedetti 2009 pages 
65ff.).  
1.3.6. Factors, which Contribute to the Magnitude of the Placebo Effect 
Prior positive experiences with the active substance resulting in a conditioning 
process and verbal suggestions leading to an expectation of pain relief can 
contribute to the placebo response (Price, Chung et al. 2005). This effect can also 
occur in the opposite direction, leading to a nocebo effect, in our case pain 
increase, when negative expectations are predominant (Petrovic 2008). 
The overall context and setting, in which the placebo is administered, namely how 
and by whom, further shapes the placebo response (Benedetti, Carlino et al. 2011). 
Placebos administered by a doctor with a white coat in a clinical setting result in a 
higher magnitude of the placebo response. The context being it experimental or 
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clinical determines further the magnitude of the placebo effect. Patients tend to 
have higher pain relief after placebo administration in a clinical setting than 
participants in an experimental setting. This can be attributed to the differences in 
expectations and desire for pain relief between patients and participants in clinical 
trials (Benedetti 2009 pages 65ff.).  
Finally a placebo response does not necessarily require a conscious expectation. 
After conditioning and learning processes placebo effects occur without conscious 
expectancies regarding the placebo. This has been particularly reported for 
hormonal responses (Benedetti, Pollo et al. 2003, Price, Finniss et al. 2008). As for 
pain, different results have been reported. 
1.3.7. Neural and Physiological Mechanisms of Placebo Analgesia 
The placebo analgesia leads to a reduction in pain related brain areas and an 
increased activity in pain modulatory circuits combined with an activation of the 
endogenous opioid and dopaminergic systems (Benedetti, Carlino et al. 2011, 
Wager and Fields 2013 page 12). The descending pain modulatory network 
described above is involved in placebo analgesia. Naloxone antagonizes placebo 
analgesia, implicating an activation of the endogenous opioid system via the 
placebo (Levine, Gordon et al. 1978, Benedetti 1996, Benedetti, Mayberg et al. 
2005, Eippert, Bingel et al. 2009). These findings were supported by positron 
emission tomography (PET) studies, which investigated the neurotransmitter 
binding character during placebo analgesia. Placebo analgesia is attended by a 
higher binding of µ-opioid receptors in limbic brain regions (Zubieta, Bueller et al. 
2005, Atlas and Wager 2012). Furthermore, the prefrontal cortex as initiating centre 
and activity in µ-opioid receptor rich brain regions as the rACC and the PAG 
influence the processing of pain (Bingel, Lorenz et al. 2006, Bingel, Tracey et al. 
2012). 
A recent study investigated placebo responses conditioned by non-steroidal anti-
inflammatory drugs, which then were antagonized by CB1 cannabinoid receptors 
(Benedetti, Amanzio et al. 2011). These findings suggest an involvement of the 
endogenous cannabinoid system in addition to the opioidergic system and support 
the idea of a response, which is specifically shaped by prior conditioning processes. 
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Placebo analgesia can therefore be mediated by both, opioid and non-opioid 
pathways, depending on the type of drugs used for conditioning (Benedetti, 
Amanzio et al. 2011, Benedetti, Thoen et al. 2013).  
Furthermore, cholecystokinin can antagonize placebo analgesia, but only when 
administered openly suggesting an involvement already on the expectancy level 
through activation of the endogenous opioid system. The cholecystokinin antagonist 
proglumide accordingly reinforces placebo analgesia. The investigation of the 
cholecystokinin system was useful in exploring the neurochemistry of nocebo 
hyperalgesia and lead to the conclusion that cholecystokinin inhibits not only 
placebo responses but also increases nocebo-induced hyperalgesia (Benedetti 
1996, Benedetti, Amanzio et al. 1997, Benedetti, Amanzio et al. 2006, Wagner, 
Roeder et al. 2013). As cholecystokinin is closely associated with anxiety, it has 
been concluded that nocebo responses are associated with increased anxiety and 
as a result with higher pain (Lydiard 1994, Atlas and Wager 2012).  
As pointed out above the dopaminergic reward system also contributes to placebo 
analgesia. The higher the activation in the nucleus accumbens – a central structure 
of the dopaminergic reward system – the greater the responsiveness to the placebo 
administration. The placebo responsiveness seems to be closely related to the 
functioning of the reward system and dopamine-related traits (Scott, Stohler et al. 
2007, Schweinhardt, Seminowicz et al. 2009). Nocebo responses lead to a 
decrease in dopaminergic activity, leading to the conclusion that placebo and 
nocebo responses are associated with opposite opioid and dopaminergic activity 
(Scott, Stohler et al. 2008). Figure 10 displays the dopaminergic and opioid systems 
involved in placebo analgesia.  
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Figure 10. Neural Correlates of Placebo and Nocebo Responses to Pain. 
A inhibitory top down effect is mediated by the opioid system starting at the cerebral 
cortex projecting to the hypothalamus (HYP), the periaqueductal grey (PAG), 
rostroventromedial medulla (RVM), and the spinal cord. The dopaminergic system 
starts at the ventral tegmental area (VTA). It then projects to the nucleus 
accumbens (NAcc). The cholecystokininergic (CCKergic) system antagonizes the 
opioid induced analgesia (Benedetti, Carlino et al. 2011). 
In summary, it can be stated that placebo analgesia is modulated by conditioning, 
suggestions and expectations. The positive outcome of the placebo treatment 
further depends on the psychosocial context in which the treatment is embedded. 
Brain regions, which are responsible for emotional, attentional and cognitive 
modulation of pain, are also activated during placebo analgesia, suggesting a 
common pain modulatory network as basis (Wiech, Ploner et al. 2008, Bingel, 
Tracey et al. 2012, Bushnell, Čeko et al. 2013).  
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1.4. fMRI 
1.4.1. MRI Mechanisms 
Magnetic resonance imaging (MRI) is used in clinical practice and scientific 
research as a non-invasive diagnostic method generating anatomic and functional 
images. This technique uses the spin of hydrogen atoms to generate its images. 
Most of the body tissue consists of water, which is made up of two hydrogen and 
one oxygen atom. Hydrogen therefore produces the strongest signal as it presents 
the bulk of the body’s tissue (Horsfield 2005, Reiser, Kuhn et al. 2011 page 80). 
A hydrogen atom consists of atomic nuclei with one proton of positive elementary 
charge and one negative electron in its shell. Due to the oddness of its atomic 
nuclei, the hydrogen proton has a spin, which is a general trait of elementary 
particles. This spin angular momentum around its own axis generates a magnetic 
dipole and thus creates a magnetic field. When placed in an external magnetic field 
B0, the spin as a vector aligns in the direction of the field. As the atom consists of 
protons, neutrons and electrons of which all contribute to the angular momentum, 
the vector does not align completely in the magnetic field, but rotates around it. This 
rotation in the direction of the external magnetic field comparable to a gyroscope is 
called precession (Balter 1987, Weishaupt, Köchli et al. 2006, Schneider and Fink 
2007, Reiser, Kuhn et al. 2011 pages 79ff.). For simplification purposes, this work 
further concentrates on the movement of the proton of hydrogen. 
The precession’s frequency is also called Lamor frequency and can be determined 
by the Lamor equation. This frequency is proportional to the strength of the external 
magnetic field, which is crucial for magnetic resonance imaging (Horsfield 2005, 
Schneider and Fink 2013 pages 62ff.). Figure 11 demonstrates the rotation around 
the dipole vector. 
Introduction 
 48 
 
Figure 11. The Dipole Vector in the Magnetic Field. 
The dipole vector demonstrates the rotation around the vector in the direction of the 
external magnetic field B0 (Balter 1987). 
Precessing protons align in the magnetic field in two different stages, parallel and 
antiparallel. The protons, which align parallel to the external magnetic field, are in a 
stable low energy state whereas the antiparallel alignment represents the unstable 
high-energy condition (Balter 1987, Reiser, Kuhn et al. 2011 pages 79ff., Schneider 
and Fink 2013 pages 62ff.). Figure 12 describes the different stages of the protons 
being parallel or antiparallel to the magnetic field. 
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Figure 12. Phase Relations Between Protons.  
Proton A is antiparallel, protons B C  D are parallel to the magnetic field B0 (Balter 
1987). 
When adding together the magnetism of the spin of each proton, we receive the net 
magnetization, which points in the direction of the applied field. As this net 
magnetization is proportional to the magnetic field applied, a strong MRI magnet is 
necessary to generate a signal. However, as it is still too small and difficult to 
measure, the net magnetization has to be reinforced (Horsfield 2005, Weishaupt, 
Köchli et al. 2006).  
This can be accomplished by exposing the patient to a high-energy radiofrequency 
impulse perpendicular to the magnetic field B0. If this energy matches the spin 
speed of the proton, then the proton absorbs the energy and deflects it out of 
alignment. Protons, which were aligned in the direction of the net magnetic field B0, 
will flip around for 90° and will initially precess synchronously (Weishaupt, Köchli et 
al. 2006, Schneider and Fink 2013 pages 62ff.).  
1.4.2. T1 Relaxation Time 
The protons precess in transversal direction of the magnetic field (z vector), they flip 
back to their original state in longitudinal alignment in z-direction. This longitudinal 
relaxation is affiliated with transmission of energy, which can be detected by the 
scanner. This effect is also called spin-lattice time as energy is transferred to the 
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lattice, which causes the lattice molecules to vibrate and in a next step convert this 
energy into heat. The spin-lattice relaxation measures the time until the protons 
reach the equilibrium state in longitudinal direction. It depends on the tissue type 
and the strength of the magnetic field applied. The time constant for this decay is 
called T1 (Suetens 2009, Schneider and Fink 2013).  
1.4.3. T2 Spin-Spin Relaxation  
After the high-energy radio frequency impulse the protons rotate in phase and are 
therefore synchronized. However, each proton has a slightly different magnetic field. 
Due to these spin-spin interactions protons precess at different angular frequencies 
and start to dephase. The spin-spin relaxation is transverse and highly dependent 
on the tissue type as different tissues relax in different ways. The time constant for 
this decay is called T2. The inhomogeneity created by the scanner and the corps 
itself leads to an even more rapid dephasing (T2* weighted time constant) 
(Weishaupt, Köchli et al. 2006). Figure 13 displays the different mechanisms of 
relaxation times T1 and T2.  
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Figure 13. Relaxation Times. 
The different mechanisms of Relaxation behind T1 and T2 relaxation, which occur 
simultaneously (Suetens 2009). 
1.4.4. BOLD Response – Functional Magnetic Resonance Imaging 
Functional magnetic resonance imaging (fMRI) is an imaging method, which 
enables the display of dynamic processes of brain activation. The underlying effect 
is the change in cerebral blood flow assuming that a haemodynamic response – an 
increase in blood flow after brain activity – can be correlated with increase in neural 
activity (Poldrack, Mumford et al. 2011). 
Essential for this imaging technique is that oxygenated haemoglobin has different 
magnetic characteristics than deoxygenated haemoglobin, deoxy-haemoglobin 
being paramagnetic to the brain tissue whereas oxygenated haemoglobin is 
isomagnetic (Matthews and Jezzard 2004, Poldrack, Mumford et al. 2011). When 
neurons become active also the blood flow in the particular brain region increases 
(Poldrack, Mumford et al. 2011) this correlation is referred to as hemodynamic 
response. Interestingly, more oxygenated haemoglobin is supplied than needed, so 
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in total the oxygenated haemoglobin increases in the activated areas (Fox and 
Raichle 1986, Matthews and Jezzard 2004, Poldrack, Mumford et al. 2011). The 
blood flow increase is significantly higher than the oxygen metabolic rate resulting in 
a reduction of the oxygen extraction fraction (Buxton 2009 page 7). Already early 
PET studies demonstrated a correlation between increased blood flow and 
increased metabolic rates (Fox and Raichle 1986). Ogawa was the first to 
demonstrate in rats that metabolic activity of the brain tissues correlates with the 
oxygen supply in that area and thus its blood flow (Ogawa, Lee et al. 1990). These 
findings, the blood oxygen level dependent (BOLD) contrast, were later replicated in 
human brains (Ogawa, Tank et al. 1992). The increase in oxygenated haemoglobin 
results in an increased MR signal in T2* weighted images. The increase in 
oxygenated haemoglobin (oxyHB) after neuronal activity is delayed in time 
(Matthews and Jezzard 2004, Schneider and Fink 2013). Figure 14 shows the 
underlying mechanisms of the hemodynamic response responsible for a normal or 
increased signal. 
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Figure 14. The Hemodynamic Response.  
The BOLD effect and its underlying hemodynamic mechanisms during basal state 
and neural activity. Oxygenated haemoglobin (oxyHb); deoxygenated haemoglobin 
(deoxyHb); cerebral blood flow (CBV) (Matthews and Jezzard 2004). 
The BOLD effect varies from 0,5% to 5% oft he MRI signal at 1,5 Tesla. In order to 
clearly distinguish it from the noise, larger voxel sizes and thus a lower spatial 
resolution of the epi (echo-planar imaging) sequence has to be selected (Schneider 
and Fink 2013 page 77). Furthermore the pre-processing of the fMRI data and the 
following statistical analysis enhance the real signal (see chapter below). In 
comparing the neural activity to baseline condition (no stimulus presented), the 
amplitude of the BOLD signal during stimulus presentation can be detected. It is 
important to keep in mind that fMRI is an indirect method to determine neural 
activity. Logothesis et al. (2001) demonstrated a direct correlation of the BOLD 
signal and neural activity by coupling electrophysical methods (microelectrodes) 
and fMRI techniques in monkeys (Logothetis, Pauls et al. 2001). It thus reflects 
neural activity. However, the exact physiological mechanisms of the BOLD signal 
have not been clearly identified yet. 
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1.5. Research Question 
In the present study we compared the analgesic placebo effect of a placebo pill 
labelled with a trusted brand as compared to a placebo pill labelled with a generic 
brand. A trusted brand may elicit and reinforce positive expectations towards the 
effectiveness of a treatment. Underlying mechanisms can be advertisement, prior 
positive experiences, and memories. Humans tend to find a strong brand and 
expensive products more appealing than a weak brand and cheaper products. 
Several fMRI studies have investigated the underlying neurofunctional mechanisms 
(McClure, Li et al. 2004, Schaefer and Rotte 2007, Plassmann, O'Doherty et al. 
2008) suggesting that a trusted brand itself can act as a placebo (Berns 2005, 
Borsook and Becerra 2005, Irmak, Block et al. 2005, Shiv, Carmon et al. 2005).  
Geuter et al. (2013) investigated the behavioural and neural responses to weak and 
strong placebo interventions. They established these interventions with a 
preconditioning phase combined with verbal instructions of price levels. The weak 
placebo condition was implemented by a preconditioning phase with lower pain 
relief and verbal instructions of a cheap price. Participants in the strong placebo 
group experienced higher pain reduction during the preconditioning phase 
combined with the verbal information of a high price. The weak placebo elicited a 
lower behavioural placebo response and neural activations, whereas the strong 
placebo resulted in higher placebo analgesia and activated brain areas (Geuter, 
Eippert et al. 2013). 
The study by Geuter et al. thus investigated the behavioural responses and neural 
correlates of expectations created by a weak and a strong placebo. The two types 
of conditioning combined with according verbal instructions lead to the 
corresponding high or low expectations of pain relief. Our aim was to solely focus 
on the brand effect of the placebo treatment. We aimed to investigate how a brand 
and its associated marketing cues might change the analgesic behavioural and 
neural response to a placebo pill. By introducing a branded and a generic ‘drug’, we 
provoked cognitive cues and expectations associated with the one or the other and 
focused on behavioural and neural placebo responses to original versus generic 
brands. 
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A recent review published by Plassmann et al. (2015) summarized findings for 
marketing-based expectations on a behavioural and neural level. The authors could 
identify individual properties and character traits as somatosensory awareness, 
reward responsiveness and the need for cognition, which shape and influence the 
“marketing placebo effects”. The authors first reviewed pain placebo studies to 
identify determinants of expectancy effects and concluded that dopaminergic 
functioning influences the expectations and therefore the placebo effect. A positive 
cue may increase the motivational aspect of reward seeking, and therefore the 
character trait of reward responsiveness may increase the analgesic response. In 
our study, we tested for individual character trait differences in order to rule out 
significant differences in personality traits and to concentrate on the brand effect 
only. Furthermore, Plassmann et al. identified the individuals’ somatosensory 
processing as another variable in their model of marketing placebo effects. Finally 
they argue that prefrontal activity with its involvement in emotional and cognitive 
regulation and assessments further shapes the placebo effect (Plassmann and 
Weber 2015). In our study, we studied expectancy effects reinforced by a strong 
brand possibly to be influenced by factors as cognitive control, emotional appraisal 
and attention. We used a paradigm, which focused on the comparison of brand and 
generics ruling out different character state and traits with questionnaires. 
Plassmann et al., however, were investigating personality traits and anatomical 
brain conditions to predict the outcome of marketing placebo effects. Differences of 
grey matter in the striatum, somatosensory cortex and prefrontal area were linked to 
personality traits as reward seeking, cognitive evaluation and emotional appraisal, 
which determined the responsiveness toward marketing placebo effects 
(Plassmann and Weber 2015). The authors concentrated on the identification of 
individual differences to predict the marketing placebo effects. In our case, we 
aimed to investigate how a brand and its associated marketing cues might change 
the analgesic behavioural and neural response despite any individual differences. 
By introducing a branded and a generic drug, we provoked cognitive cues and 
expectations associated with the one or the other and focused on behavioural and 
neural placebo responses to original versus generic brands. 
In this study, we tested the hypothesis that placebo-induced expectations reinforced 
by a strong brand can enhance the neuronal impact of an inert substance described 
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as a painkiller. For this research aim we tested two identical placebos against each 
other, one labelled as ‘Aspirin’, the other one as ‘1A Pharma’ as a generic brand of 
Aspirin. We expected a higher pain relief in the Aspirin placebo group as compared 
to the 1A Pharma placebo group. Furthermore we investigated the neural correlates 
of the different placebo responses. 
This line of research is clinically important, since it could demonstrate to what extent 
brand labelled drugs evoke a placebo effect in patients, and therefore which 
consequences it may have if doctors switch a known and proven medication to its 
generic equivalent. Moreover, it could show how psychosocial stimuli, such as 
verbal and nonverbal cues, can influence both pain perception and pain processing 
to the good or to the bad. The higher cost of original versus generic drugs is a 
further reason for exploring the underlying neural processes. The placebo study of 
Geuter et al. (2013), which investigated the differences in efficacies between weak 
and strong placebos induced by experience, verbal information and value 
manipulation (Geuter, Eippert et al. 2013), inspired us to investigate the effect of a 
trusted brand in comparison to a generic brand. The research aims of our pilot study 
were (1) to test, whether a placebo pill described as Aspirin elicits a larger analgesic 
response than a placebo pill labelled as the generic drug 1A Pharma, and (2) to 
identify the underlying neural correlates of this putatively differential placebo effect. 
  
Materials and Methods 
 57 
2. Materials and Methods 
2.1. Participants 
Thirty male right-handed subjects between the age of 27 and 45 with no history of 
psychiatric, internal, neurologic disease or drug abuse were selected. The 
recruitment was based on an existing database of the lab as well as on a university 
database of potential participants for medical studies.  We used a specific selection 
questionnaire to choose potential candidates (as shown in appendix 6.1).  
The questionnaire enabled the selection of participants with occasionally use of 
painkillers and enabled the exclusion of participants with psychological, neuronal 
and major systemic disease, left handiness and metal implants. 
The study was conducted in accordance with the Declaration of Helsinki and the 
protocol was approved by the ethics committee of the Ludwig-Maximilians-
University Munich (LMU). Written informed consent was provided, and subjects 
received financial compensation of 150 Euros. 
2.2. Medoc 
The thermal stimuli were conducted via a 30x30 mm 2  Medoc Pathway thermode of 
the model ATS (Advanced Thermal Stimulation, Medoc Advanced Medical Systems 
Ltd, Ramat Yishay, Israel). The thermode was placed on the left volar forearm 
corresponding to dermatome 6 (Ruscheweyh, Verneuer et al. 2012, Geuter, Eippert 
et al. 2013). The Medoc system enables accurate programmable temperature 
applications between -10ºC and 55ºC with a temperature increase of 6º C per 
second.  
It was used as a somatosensory stimulator to induce temperatures between 42-47 ° 
corresponding to 60/100 on the numeric rating scale. 
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2.3. The Placebo Agent 
Each participant received a dose of the placebo dissolved in water. Fabian 
Simmank and Lea Maikowski were responsible for developing the placebo agent 
using a formula derived from Aspirin. The placebo agent was inspired by Aspirin 
plus c in look and taste. It was based on the composition and ingredients of Aspirin 
excluding the active agent to produce a similar taste. The ingredients of placebo 
were the following: 
• ascorbic acid 
• sodium hydrocarbonate 
• saccharose 
• cellulose 
• maize starch 
It was dissolved in 80 ml water in front of the eyes of each participant and then 
administered. 
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2.4. The Instructions 
During the native condition before the scanner session all participants received the 
following information:  
 
Figure 15. Instructions Native Condition. 
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After the randomization into the two placebo groups, the participants of the branded 
placebo group (Aspirin group) received the following information:  
Figure 16. Instructions Aspirin. 
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The generic placebo group received the following hand-out:  
Figure 17. Instructions 1A Pharma. 
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2.5. Procedure and Materials  
This chapter describes the procedure of the experiments (Fehse, Maikowski et al. 
2015). A 2x2 prospective block design was used in our study. We conducted a 
within-subjects design comparing the native with the intervention condition (before 
and after placebo administration) and a between subjects design comparing the two 
placebo interventions (Aspirin and 1A Pharma). The study design was single 
blinded. Thirty male right-handed subjects participated. After the native 
measurement, the subjects were randomly assigned to either the “Aspirin” group or 
the “1A Pharma” group. Lea Maikowski (L.M.) and Dr. Evgeny Gutyrchik conducted 
randomization by lot drawing. For this, the names of all participants were separately 
written on paper and L.M. drew the names alternately for assigning the participants 
to the two groups. Dr. Gutyrchik supervised the randomization. Then both groups 
received group-specific, standardized and written information on the respective 
brand as displayed in the chapter above. 
Thereafter, all participants received the same placebo solution in the form of an 
inert substance based on the formula of Aspirin as described above excluding the 
active agent. The placebo application was always conducted by the same person 
(L.M.) wearing a white coat and being introduced as medical student.  
Before participants went into the native round, they rated the average and maximum 
expected pain. After the native condition, they rated the mean and maximum 
perceived pain. After receiving the group-specific information, participants had to 
rate again their mean and maximum expected pain. Finally after the intervention 
round, the subjects rated the mean and maximum pain they experienced.  
Figure 18 describes the study design with the native condition and the intervention 
condition. 
  
Materials and Methods 
 63 
 
Figure 18. Study Design: 2x2 Block Design. 
The participants first underwent the native condition. After that, they were randomly 
assigned to either the original brand placebo group or the generic brand placebo 
group and received according information before they underwent the intervention 
condition. 
Before the actual experiment, we started with a calibration trial. To determine the 
individual pain threshold a calibration was conducted with Medoc Model Pathway 
ATS. The calibration process took place at the day of the testings’ prior to the first 
paradigm. The participants were instructed to rate the pain intensity on a numeric 
rating scale (NRS) between 0 and 100, 100 being the worst unbearable pain and 0 
no pain. The aim was to determine the individual temperature that corresponds to 
the value of 60 at the scale. The Medoc thermode was placed on the right forearm 
corresponding to dermatome 6. Between 1 and 3 runs were conducted starting with 
a temperature of 42 degrees to a maximum of 47 degrees. Each temperature 
impulse lasted for 20 seconds and was followed by a pause and the rating. As soon 
as the value of 60 on the NRS was determined the calibration process was finished. 
The 2x2 prospective parallel group block design was used, consisting of 2 blocks 
with duration of 4000ms per condition. For the native round 30 subjects participated. 
Then as described above, the participants were randomly equally assigned to the 
two different intervention groups, so at the beginning of the intervention condition, 
15 participants were assigned to the placebo condition Aspirin and 15 to the generic 
placebo condition. 
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Subjects viewed the screen via a mirror attached to the head-coil on a liquid-
chrystal display (LCD) screen behind the scanner. Prior to the first paradigm, the 
participant was presented a short introduction and instruction in the following 
sequence for 2000 milliseconds (ms). 
Then the actual first paradigm - the native test - started with a 1000 ms prime (a 
pixelated picture). In the pain phase a red dot over a black screen was displayed for 
2000 ms whilst the temperature stimulus corresponding to the individual rating was 
applied. Consecutively a pause for 1000 ms followed. This paradigm was repeated 
6 times and afterwards the subjects evaluated the maximum and average/mean 
pain. The paradigm was then repeated, and ended after 12 trials in total. Figure 19 
displays the time course of the study design. The behavioural pain questionnaire, 
which the participants filled out after the native and after the intervention round is 
shown in appendix 6.2 below.  
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Figure 19. Time Course of the Study. 
A block design was used consisting of 12 native runs followed by 12 intervention 
rounds. 
After the first run, the native run, the participant was placed in a room outside the 
scanner. The subject received the placebo labelled as Aspirin or 1A Pharma 
together with information about the brand (see chapter above). Between 25 and 45 
minutes were granted for the administered medication to take effect. During that 
waiting period, the participants had to fill out the following questionnaires:  
• POMS profile of mood states: Momentanes Befinden – aktuelle 
Stimmungsskala, Dalbert (1994) 
• STAI-G X1 State and Trait Anxiety Inventory, Spielberger (1989) 
• BMQ Beliefs about Medicines Questionnaire, Horne (1999)  
• FPQ-III Fear of Pain, McNeil (1998) 
• PVAQ Pain Vigilance and Awareness Questionnaire, McCracken (1997) 
• SES-17 Social Desirability Scale, Stöber (2001) 
• LOT-R Revision of Life-Orientation Test, Scheier, Carver and Bridges (1994) 
The POMS profile of mood states: ASTS Momentanes Befinden – aktuelle 
Stimmungsskala, Dalbert (1994) and the STAI-G X1 State and Trait Anxiety 
Inventory, Spielberger (1989) were carried out three times; before the native 
baseline condition, during the waiting period (see paragraph above) and after the 
intervention condition.  In the following text these different points of data collection 
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are labelled with numbers 1-3 (STAI-1, STAI-2, STAI-3, POMS-1, POMS-2, POMS-
3). 
The Beliefs about Medicines Questionnaire evaluates the attitude towards 
medication use, if the person considers them as necessary and if he has 
apprehensions about the medication use. Fear of Pain Questionnaire (FPQ-III) 
assesses anxiety about pain in relation to different pain-causing stimuli (Antony and 
Stein 2009) . The Pain Vigilance and Awareness Questionnaire (PVAQ) measures 
pain related attention. The Social Desirability Scale rules out response, the person 
thinks are socially adequate, as disruptive factor. The Life Orientation Test serves 
as self-assessment instrument for individual differences of generalized optimism vs. 
pessimism. The questionnaires were raised before the native round. 
The Profile of Mood State assesses the momentary affective mood. The State and 
Trait Anxiety Scores assess the actual and character based fear to diagnose 
anxiety and depressive syndromes. The participants had to complete the 
questionnaires before the native round, in-between the native and the intervention 
condition after receiving the group-specific information, and finally after the 
intervention round.  
In the second condition, the time setup was identical to paradigm 1, the instruction 
consisted either of information about 1A Pharma or Aspirin and the prime picture 
was the package of the corresponding brand. A total of 12 trials and two ratings as 
in the paradigm 1 were compiled. Figure 20 shows the experimental design for the 
branded placebo condition.   
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Figure 20. Experimental Design. 
A fixation cross was used during the baseline condition. The acetylsalicylic acid 
(ASA) packaging either of Aspirin or 1A Pharma was used for anticipation. The heat 
application via thermode was indicated by a red dot (Fehse, Maikowski et al. 2015). 
2.6. Data Processing and Analysis 
A 3T whole body system (Magnetom VERIO, Siemens, Germany) at the University 
Hospital Großhadern of the Ludwig-Maximilians-University Munich (LMU) equipped 
with a standard A TIME head coil was used for fMRI scanning. The participants’ 
heads were held in comfortable foam cushions in order to minimize head 
movements. 
A T1-weighted, magnetization-prepared rapid gradient echo (MPRAGE) sequence 
was generated as anatomic reference with the following parameters: repetition time 
(TR) = 2400 ms, echo time (TE) = 3.06 ms, flip angle (FA) = 9°, number of slices = 
160, field of view (FOV) = 240x256 mm, matrix = 224x256 and rect. FOV = 7/8. The 
structural images were acquired in the sagittal orientation. For the blood-oxygen-
level-dependent (BOLD) functional imaging, a T2*-weighted echo-planar imaging 
(EPI) sequence was used with the following parameters: TR = 2500 ms, TE = 30 
ms, FA = 80°, number of slices = 38, slice thickness = 3 mm, inter-slice gap = 0.4 
mm, interleaved acquisition, spatial resolution 1 mm 3, FOV = 192x192 mm, matrix 
= 64x64, and in-plane resolution = 3x3 mm. The functional images were acquired in 
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axial orientation (parallel to the anterior commissure–posterior commissure [AC-PC] 
line) covering the whole brain. 
2.6.1. Pre-processing of fMRI Data 
During pre-processing, we made the data suitable for further analysis. We 
conducted the following steps: slice-timing, realignment, co-registration and 
smoothing. In the following paragraphs these steps are described in detail. 
2.6.2. Slice-timing 
High spatial resolution requires acquisition of many thin slices. Depending on the 
repetition time/interscan interval (TR) the acquisition of volumes can take up to 
several seconds. So not every slice is generated at the same time, whereas SPM 
analysis assumes the generation at one point in time (Henson, Buechel et al. 1999, 
Poldrack, Mumford et al. 2011, Sladky, Friston et al. 2011). A correction of the time 
differences in the acquisition of slices is essential for further analysis. The positive 
effect of this correction is especially crucial for event related designs (Sladky, 
Friston et al. 2011), but block designs have to account as well for the differences in 
acquisition time. Slice-timing corrects this temporal offset making the data 
processable for statistical analysis (Poldrack, Mumford et al. 2011). As a result, all 
slices of an image are represented at one point in time for the following analysis. 
2.6.3. Motion Correction: Realignment 
To compare different brain activations voxels (= volume element in a three 
dimensional space) have to correspond to the same brain regions. Head motions 
lead to distortions and a mismatch of these corresponding brain areas. Motion 
correction accounts for this in adjusting all volumes to a reference picture. Usually 
the first picture generated (Schneider and Fink 2007) or an image in the middle of 
the sequence is chosen as a reference (Poldrack, Mumford et al. 2011). The 
images are then realigned to this reference image by calculating conformities along 
the volumes. 
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2.6.4. Co-registration 
The co-registration process is essential to localize the activated brain regions. As 
functional fMRI images have a low spatial resolution, co-registration merges these 
images with anatomic images to facilitate a more precise localization of the 
activated brain area (Schneider and Fink 2007).  
2.6.5. Normalization 
Normalization is essential for a comparison between the participants, as there exist 
differences in size and shape of their brains. The fMRI images are fitted to a 
standardized Echo-Planar-Imaging (EPI) template. Thus every individual brain will 
be displayed on a standard brain enabling further second level analysis. The 
Montreal Neurological Institute’s Brain is usually used as the reference brain 
(Schneider and Fink 2007 page 156). As a common template, a standard MNI-
space was developed on the basis of 305 brains of healthy participants (Poldrack, 
Mumford et al. 2011). 
2.6.6. Smoothing 
The last step of pre-processing is called smoothing. The fMRI data show spatial 
correlations due to functional similarities of adjacent brain regions. Smoothing uses 
a three-dimensional gauss distribution (full width at half maximum) as filter, thus 
eliminating random fluctuations and enhancing the real signal by improving the 
signal-to-noise ratio (Turner, Howseman et al. 1998, Schneider and Fink 2007 page 
157). Furthermore the comparability between subjects is improved by spatial 
smoothing thereby reducing a mismatch across individuals (Poldrack, Mumford et 
al. 2011). The following figure 21 of Van Horton, Grafton et al. (2004) summarizes 
the steps in the pre-processing process of fMRI data. 
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Figure 21. FMRI Data Processing Pipelines. 
(Van Horn, Grafton et al. 2004) 
2.7.  Statistical Methods 
FMRI data were analysed with SPM8 (Statistical Parametric Mapping; 
http://www.fil.ion.ucl.ac.uk/spm). The first six volumes were discarded to account for 
T1 saturation effects. All functional images were realigned, co-registered to the EPI 
template (Montreal Neurologic Institute, MNI), spatially normalized into standard 
stereotaxic space using standard SPM8 parameters, re-sliced to 2 × 2 × 2 mm 
voxels, and smoothed with an [8 8 8] mm full-width at half maximum (FWHM) 
Gaussian kernel. Each condition (picture, pain) was modelled by a boxcar function 
convolved with the canonical hemodynamic response function. This statistical 
method is the common procedure in our Lab (Park, Gutyrchik et al. 2014). At the 
first level, t-tests were computed for each subject and for each condition. The 
individual contrast images for each subject were used for the random-effects 
second level analysis. A 2 x 2 model was computed for the pain condition with one 
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between-subjects factor (Aspirin/1A Pharma group) and one within-subjects factor 
(before/after intervention). The statistical parametric maps were cluster-level 
thresholded at p (FWE) < .05 (starting from p uncorrected < .01). Anatomical 
descriptions were based on the AAL atlas (Automated Anatomical Labelling of 
Activations; Tzourio-Mazoyer & Landeau, 2002).  
Behavioural data were analysed by using SPSS Version 21.0 (IBM Corp., Amornk, 
NY). All data were tested for normal distribution and were analysed accordingly by 
either parametric or nonparametric statistical tests. P-values < 0.05 were regarded 
significant. 
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3. Results 
3.1. Participant Characteristics 
As described above, thirty male right-handed subjects between the age of 27 and 
45 (mean age = 31.86 years, SD = 6.39) with no history of psychiatric, internal, 
neurologic disease or drug abuse were recruited. Three participants were excluded 
during the experiment: One participant had to be excluded due to hyperalgesia 
during the native round (baseline) in the scanner, the second participant because of 
a skin reaction after the native round. The third participant cancelled study 
participation on the study day.  
The two placebo groups were comparable in particular as regards to the 
psychosocial variables, pain expectancies, and pain evaluations in the native round. 
Concerning their age, the two groups differed significantly (see Table 1).  
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Table 1. Comparison of Groups at Baseline (means ± standard deviations). 
  Placebo 
Brand 
Placebo 
Generic 
p-value 
Gender m m ---  
Age 35.25 ± 8.87 29.00 ± 2.59 0.035a 
Temperature 46.00 ± 0.95 45.73 ± 1.28 0.702a 
 
Pain Ratings NRS       
Mean Pain native 54.58 ± 16.16 56.63 ± 11.76 0.706b 
Maximum Pain native 70.00 ± 10.87 69.90 ± 13.34 0.983b 
 
STAI-G X1       
STAI-1  49.04 ± 2.10 47.38 ± 2.47 0.094b 
 
POMS       
POMS-Trauer-1 3.27 ± 0.47 3.75 ± 0.29 0.594a 
POMS-Hoffnungslosigkeit-1 3.27 ± 0.65 3.08 ± 2.89 0.462a 
POMS-Müdigkeit-1 8.73 ± 3.93 9.50 ± 4.81 0.950a 
POMS-positive Stimmung-1 27.64 ± 5.33 27.08 ± 7.60 0.804a 
POMS-Zorn-1 3.09 ± 0.30 3.83 ± 1.59 0.147a 
 
BMQ       
BMQ General Overuse 10.00 ± 2.26 10.20 ± 2.68 0.980a 
BMQ General Harm 15.25 ± 1.29 14.80 ± 1.86 0.502a 
BMQ General Benefit 7.33 ± 2.19 8.60 ± 2.03 0.096a 
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FPQ-III       
Pain minor 21.50 ± 7.78 18.87 ± 6.00 0.338a 
Pain severe 36.83 ± 5.70 34.53 ± 6.65 0.492a 
Pain medical 28.42 ± 7.61 23.93 ± 5.89 0.149a 
Pain total 86.75 ± 19.72 77.33 ± 16.75 0.222a 
 
LOTR       
LOTR Pessimism 11.08 ± 1.68 10.60 ± 2.41 0.423a 
LOTR Optimism 4.92 ± 1.16 6.47 ± 2.47 0.065a 
LOTR Optimism 1-dimensional 6.00 ± 2.09 8.20 ± 3.57 0.080a 
 
PVAQ       
PVAQ 40.92 ± 12.57 32.53 ± 8.85 0.053b 
 
SES       
SES 10.92 ± 3.42 9.40 ± 2.50 0.195b 
Abbreviations: NRS, Numeric rating scale; STAI-G X1, State Anxiety Inventory; 
POMS, Profile of mood states; BMQ, Beliefs about Medicines Questionnaire; FPQ-
III, Fear of Pain; LOT-R, Revision of Life-Orientation Test; PVAQ, Pain Vigilance 
and Awareness Questionnaire; SES-17, Social Desirability Scale. 
a Mann-Whitney-U-Test 
b ANOVA  
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3.2. Behavioural Results 
3.2.1. Mean Pain Ratings 
Mean pain ratings decreased significantly from the native to the intervention 
condition (Ftime(1,25) = 7.725, p = 0.010). The decrease in mean pain ratings from 
the native condition to the intervention condition differed non-significantly between 
the two placebo groups, as shown by the time-by-condition interaction (Fint (1,25) = 
3.231, p = 0.084). Given the trend for significance and the small sample size, we 
performed post-hoc tests and observed a significant decrease in mean pain ratings 
for the branded placebo (Aspirin) only. Mean pain ratings decreased significantly for 
the branded placebo group from 54.6 ± 16.2 (SD) during the native condition to 45.4 
± 15.8 (SD) after the administration of the placebo labelled as “Aspirin” (p = 0.032). 
In the generic group (1A Pharma), mean pain ratings decreased non-significantly 
from 56.6 ± 11.8 in the native condition to 54.7 ± 15.0 in the intervention condition; p 
= 0.344). Figure 22 displays the mean behavioural pain ratings before and after the 
intervention. 
 
Figure 22. Mean Behavioural Pain Ratings before and after Placebo 
Administration. 
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3.2.2. Maximum Pain Ratings 
Maximum pain ratings decreased significantly from the native to the intervention 
condition (Ftime (1,25) = 8,602, p = 0,007). The decrease in maximum pain ratings 
from the native condition to the intervention condition did not differ significantly 
between the two placebo groups (Fint (1,25) = 2.783, p=0.108).  
3.2.3. Pain Expectancies 
Regarding pain expectancies after the administration of the two different placebos, 
the expected mean pain intensities differed significantly between the two placebo 
groups (p = 0.022). Participants in the „Aspirin“ group expected an average pain of 
36.67±13.37 (SD), whereas in the „1A Pharma“ group mean pain intensities of 
49.64±13.51 (SD) were expected (figure 23). 
The maximum expected pain did not differ significantly between the two placebo 
groups (p = 0.242). In the branded group “Aspirin” maximum pain ratings were 
57.08±14.05 (SD), whereas participants in the generic group expected maximum 
pain intensities of 64.64±17.48 (SD). 
 
Figure 23. Expected Mean Pain Intensities before the Intervention Round after 
Receiving Group Specific Information. 
0	  
10	  
20	  
30	  
40	  
50	  
60	  
N
um
er
ic
	  R
at
ig
	  S
ca
le
:	  N
RS
	  
	  
Mean	  expected	  pain	  
branded	  generic:	  Aspirin	  
generic	  placebo:	  1a	  Pharma	  
Results 
 77 
3.2.4. State Anxiety 
State anxiety increased significantly from the native condition STAI-1 to the 
intervention condition STAI 2, 3 with a general linear model (Ftime(2,44) = 3.446, p = 
0,041). We compared the state anxiety prior to the grouping (STAI-1) to the 
intervention (STAI-2 and STAI-3). The increase in state anxiety from the native 
condition (STAI-1) to the intervention condition (STAI-2, STAI-3) differed non-
significantly between the two placebo groups (Fint(2,44) = 3.104, p = 0.055). Given 
the trend for significance and the small sample size, we performed post-hoc tests 
and observed a significant increase in state anxiety for the generic placebo group 
only. Results are displayed in table 2.  
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Table 2. Comparison of Groups at Intervention Condition. 
 
Placebo 
Brand 
Placebo 
Generic 
p-value 
Pain ratings NRS       
Pain intervention - mean 45.42 ± 15.84 54.67 ± 15.02 0.133b 
Pain intervention - maximum 61.87 ± 09.48 67.67 ± 15.47 0.267b 
Pain native – intervention - mean p = 0.032b p = 0.344b 
 
Pain native – intervention - max p = 0.027b p = 0.254b 
 
3.2.4.1.1. Pain native – 
intervention - mean 
(prepost*placebo) 
  
0.084d 
Expected Pain – mean 36.67 ± 13.37 49.64 ± 13.51 0.022b 
Expected Pain – max  57.08 ± 14.05 64.64 ± 17.48 0.242b 
 
STAI-G X1       
STAI-2 48.37 ± 1.97 48.53 ± 2.17 0.839c 
STAI-3 49.44 ± 2.06 49.58 ± 2.22 0.872c 
STAI-1,2,3 (prepost*placebo) p = 0.615d  p = 0.022d 0.083d 
 
POMS       
POMS-Trauer-2 3.75 ± 1.06 3.53 ± 0.92 0.591a 
POMS-Trauer-3 3.42 ± 0.90 3.27 ± 0.59 0.737a 
POMS-Hoffnungslosigkeit-2 3.42 ± 1.16 3.00 ± 0.00 0.107a 
POMS-Hoffnungslosigkeit-3 3.25 ± 0.87 3.33 ± 1.29 0.914a 
POMS-Müdigkeit-2 8.92 ± 3.92 10.01 ± 4.20 0.462a 
POMS-Müdigkeit-3 9.20 ± 3.79 9.67 ± 4.61 0.961a 
POMS-positive Stimmung-2 27.83 ± 5.31 27.73 ± 7.45 0.419a 
POMS-positive Stimmmung-3 27.25 ± 5.55 24.13 ± 7.65 0.378a 
POMS-Zorn-2 3.17 ± 0.58 3.27 ± 0.59 0.453a 
POMS-Zorn-3 3.00 ± 0.00 3.27 ± 0.70 0.197a 
Abbreviations: NRS: numeric rating scale, STAI: state anxiety inventory; POMS: 
profile of mood states. STAI-1: state anxiety inventory before the experiment, STAI-
2: state anxiety inventory after the native scanner session, STAI-3: state anxiety 
inventory after the intervention session in the scanner. 
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a Mann-Whitney-U-test asymp. Sig. 2-seitig T-Test 
bT-Test 
cANOVA 
dAllgemeines Linerares Modell, Mixed Design 
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3.3. Neurofunctional Results 
3.3.1. Pain Condition: Native vs Post-Intervention  
We found the following results during the pain condition (Fehse, Maikowski et al. 
2015). Before the placebo administration during the native condition (pain versus 
baseline) the participants showed activations of the right and left insulae, right 
inferior frontal gyrus and right putamen, left rolandic operculum and the left inferior 
frontal gyrus. These neurofunctional activations are shown in figure 24. Coordinates 
and clusters are displayed in table 3 below. 
After placebo administration we observed bilateral activation of the insula, the 
inferior frontal gyrus, left rolandic operculum, superior temporal gyrus and the right 
putamen. Additional activations were observed in the bilateral supplementary motor 
area, bilateral medial part of the superior frontal gyrus (dorsomedial prefrontal 
cortex) and the bilateral cingulate cortex. Neurofunctional activations are displayed 
in figure 25. Coordinates and clusters are shown in table 4 below. 
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Figure 24. Neurofunctional Correlates: Pain before Placebo Administration.  
Pain versus no-pain measurement in both placebo groups (Native): Pain condition 
versus no-pain measurement in both placebo groups. L. insula: left insula; R. insula: 
right insula. x, y and z coordinates are in the MNI stereotactic space; cluster-level 
thresholded at p (FWE) < .05; neurologic convention: left is left. 
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Figure 25. Neurofunctional Correlates: Pain after Placebo Administration. 
Pain condition versus no-pain measurement in both placebo groups (Intervention). 
L. insula: left insula; R. insula: right insula; R. middle frontal g.: right middle frontal 
gyrus; L. sup. motor area: left supplementary motor area; L. sup. frontal g. medial 
part: left superior frontal gyrus medal part. x, y and z coordinates are in the MNI 
stereotactic space; cluster-level thresholded at p (FWE) < .05; neurologic 
convention: left is left. 
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Table 3. Neurofunctional Correlates: Pain before Placebo Administration 
(versus Baseline) (Fehse, Maikowski et al. 2015). 
  
 Coordinates  
Brain region cluster kE x y z Z-
value 
R. insula, R. inferior 
frontal g., R. putamen 1 440 38 22 –2 5.12 
L. insula, L. rolandic 
operculum, L. superior 
temporal g., L. inferior 
frontal g. 
2 366 –34 20 2 4.11 
Note. kE = size in voxels (2 x 2 x 2 mm). R. = right, L. = left, g. = gyrus. The x, y 
and z coordinates are in the MNI stereotactic space.  
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Table 4. Neurofunctional Correlates: Pain after Placebo Administration 
(versus Baseline) (Fehse, Maikowski et al. 2015). 
   
Coordinates  
Brain region cluster kE x y z Z-value 
R. insula, R. inferior 
frontal g. 
1 688 36 24 2 5.63 
L. insula, L. inferior 
frontal g. 
2 405 –34 20 4 4.54 
L./R. supplementary 
motor area, L./R. 
superior frontal g., 
medial part (dmPFC), 
L./R. cingulate g. 
3 652 –2 20 48 4.47 
L. inferior frontal g., L. 
rolandic operculum, L. 
superior temporal g. 
4 237 –50 8 2 4.31 
R. middle frontal g. 
(dlPFC), R. inferior 
frontal g.  
5 229 46 38 22 4.13 
R. inferior frontal g., R. 
rolandic operculum, R. 
superior temporal g., 
R. insula 
6 230 58 14 8 4.00 
Note. kE = size in voxels (2 x 2 x 2 mm). R. = right, L. = left, g. = gyrus. The x, y 
and z coordinates are in the MNI stereotactic space.  
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3.3.2. Pain Condition: Direct Comparison Between the two Placebo 
Conditions after the Intervention 
A direct comparison of the two placebo conditions (contrast “Aspirin” – “1A 
Pharma”) after the placebo administrations showed higher activations of the medial 
part of the superior frontal gyrus (dorsomedial prefrontal cortex) and the bilateral 
superior frontal and right middle frontal gyri including adjacent regions (bilateral 
precentral gyrus, bilateral cingulate gyrus and bilateral supplementary motor areas) 
in the brand group (“Aspirin”) compared to the generic group (“1A Pharma”). The 
reversed contrast – generic intervention (“1A Pharma”) compared to the brand 
intervention (“Aspirin”) – showed no significant activations. Neural correlates are 
shown in figure 26 below. Coordinates and clusters are displayed in table 5. 
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Figure 26. After Placebo Administration: Original versus Generic Analgesic 
During Pain Condition.  
L. inf. frontal g.: left inferior frontal gyrus; R. inf. and middle frontal g.: right inferior 
and middle frontal gyrus; L./R. sup. frontal g. medial part: left/right superior frontal 
gyrus medial part; R. middle frontal g.: right middle frontal gyrus; L. middle frontal g.: 
left middle frontal gyrus. x and y coordinates are in the MNI stereotactic space; 
cluster-level thresholded at p (FWE) < .05; neurologic convention: left is left.  
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Table 5. Neurofunctional Correlates: Pain after Placebo Administration: 
Original vs. Generic (Fehse, Maikowski et al. 2015). 
   
Coordinates 
 
Brain region cluster kE x y z Z-value 
R. middle frontal g. 
(dlPFC), L./R. superior 
frontal g., medial part 
(dmPFC), R. inferior 
frontal g., L./R. 
superior frontal g. 
(dlPFC), R. precentral 
g., L/R. cingulate g., 
L/R. supplementary 
motor areas 
1 3945 8 40 58 3.25 
Note. kE = size in voxels (2 x 2 x 2 mm). R. = right, L. = left, g. = gyrus. The x, y 
and z coordinates are in the MNI stereotactic space.  
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3.3.3. Anticipation  
We furthermore analysed the anticipation phase 10 seconds prior to the heat 
administration. We observed bilateral activations of the inferior occipital gyrus and 
the inferior temporal gyrus, the left middle and occipitotemporal gyrus as well as the 
right angular gyrus in the branded group in the contrast after the intervention 
compared to the native condition. Neurofunctional results are displayed in figure 27, 
the coordinates and clusters are shown in table 6 below. In the generic placebo 
group in the same contrast (anticipation intervention > native condition) activations 
in the bilateral posterior cingulate gyrus, bilateral precuneus, left middle and inferior 
temporal gyrus, bilateral straight gyrus and left hippocampus and parahippocampal 
gyrus were detected. Neurofunctional results are displayed in figures 28A and 28B, 
the coordinates and clusters are shown in table 7 below. Only these group specific 
analyses did show significant results. The combined comparison between the native 
and intervention condition as well as a direct comparison between the two placebo 
groups did not show any significant results. 
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Figure 27. Neurofunctional Correlates: Anticipation Branded Group, Contrast 
after > before the Administration of the Placebo. 
L. inf. occipital g.: left inferior occipital gyrus; L. middle occipital g.: left middle 
occipital gyrus. x, y and z are in the MNI stereotactic space; cluster-level 
thresholded at p (FWE) < .05; neurologic convention: left is left. 
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Table 6. Neurofunctional Correlates: Anticipation Original Brand after > before 
Placebo Administration. 
  
 Coordinates  
Brain region cluster kE x y z Z-value 
L.inferior occipital 
gyrus, L. middle 
occipital gyrus, L. 
inferior temporal 
gyrus, L. fusiform 
gyrus (L. 
occipitotemporal 
gyrus) 
1 331 -46 -80 –6 4.55 
Note. kE = size in voxels (2 x 2 x 2 mm). R. = right, L. = left, g. = gyrus. The x, y 
and z coordinates are in the MNI stereotactic space.  
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Figure 28A. Neurofunctional Correlates: Anticipation Generic Group, Contrast 
after > before Administration of the Placebo.  
L. inf. temporal g.: left inferior temporal gyrus; L. inf. occipital g.: left inferior occipital 
gyrus; L. post. cingulate g.: left posterior cingulate gyrus; L. precunes: left 
precuneus; L./R. straight g.: left and right straight gyrus (rectus gyrus). x, y and z 
coordinates are in MNI stereotactic space; cluster-level thresholded at p (FWE) < 
.05; neurologic convention: left is left. 
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Figure 28B. Neurofunctional Correlates: Anticipation Generic Group, Contrast 
after > before Administration of the Placebo. 
L. hippocampus: left hippocampus; L. parahippocampal g.: left parahippocampal 
gyrus; L.R. straight g.: left and right straight gyrus (rectus gyrus).  x, y and z 
coordinates are in MNI stereotactic space; cluster-level thresholded at p (FWE) < 
.05; neurologic convention: left is left. 
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Table 7. Neurofunctional Correlates: Anticipation Generic after > before 
Placebo Administration. 
  
 Coordinates 
 
Brain region cluster kE x y z Z-value 
L. middle and inferior 
temporal gyrus, L. 
inferior occipital gyrus 
1 484 –52 –66 –16 4.60 
L./R. posterior 
cingulate cortex/gyrus, 
L./R. Precuneus 
2 394 2 –54 30 4.21 
L. Hippocampus, L. 
Parahippocampal 
gyrus 
3 365 –24 –10 –20 4.94 
L./R. straight gyrus 
(rectus) 4 302 2 34 –16 4.60 
Note. kE = size in voxels (2 x 2 x 2 mm). R. = right, L. = left, g. = gyrus. The x, y 
and z coordinates are in the MNI stereotactic space.  
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4. Discussion 
We compared the analgesic effects of two different placebo interventions. The 
interventions differed in their labelling and corresponding brand information. Our 
results displayed consistent and significant differences between the two placebo 
groups, on both the behavioural and the neural response levels. Only the 
participants in the branded placebo group showed a decrease in pain intensity, 
whereas no similar behavioural response was found for the generic group. However 
as we only observed a trend for significance in the decrease of mean pain ratings 
between the two placebo groups these results should be interpreted cautiously. The 
small sample size could be an explanation and speaks for a follow up trial with a 
larger population. 
Concerning neural correlates, we found activations of the anterior insulae under 
baseline conditions. After the intervention, we observed supplementary activations 
of the dorsomedial prefrontal cortex. The direct comparison of the two placebo 
conditions showed higher activations of the bilateral dorsolateral and dorsomedial 
prefrontal cortex for the original brand compared to the generic condition (Fehse, 
Maikowski et al. 2015). Furthermore during the anticipation phase (contrast after > 
before placebo administration), we observed only for the generic group activations 
of hippocampal, parahippocampal and adjacent brain areas. 
All in all, the chosen methods fulfilled the desired requirements well. The 
experimental design and study protocol was conducted according to plan. 
We chose a 2x2 block design, which is commonly used in fMRI studies. This study 
design enabled us to analyse and compare brain activations of baseline conditions, 
anticipation and pain conditions within and between subjects in a temporal accurate 
manner. The use of Medoc, which precisely applies an individually calibrated 
noxious heat stimulus, furthermore supported the exact conduction and the success 
of the experiment. We used a sample size of 30 participants. Follow-up trials with a 
larger sample size could produce transferable findings, confirming the results of this 
pilot study.  
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Our study was carried out without prior preconditioning of the participants. In a 
preconditioning trial, participants experience real pain relief after placebo treatment, 
as for example, the intensity is turned down after the placebo intervention, while 
during the real experiment, intensities remain unchanged. These preconditioning 
trials can be carried out in pain placebo experiments to boost the placebo response 
(Geuter, Eippert et al. 2012, Schenk, Sprenger et al. 2014). We were able to 
generate significant results even without the enhancement effect of preconditioning. 
This supports the finding of a strong placebo response under the branded placebo 
condition. In the future, an investigation of the same differences with the addition of 
a preconditioning phase would be interesting to carry out. 
Although we can summarize the evaluation of our applied methods overall 
positively, the limitations of our study suggest a follow-up trial with a larger sample. 
A prior preconditioning trial could reinforce the placebo response and the underlying 
neural correlates. Another interesting question is the investigation in how a double 
blind design, would affect the results, in order to disentangle the influence of the 
medical personnel, which administers the agent. 
As regards to the observed results, our data demonstrate that only the original 
brand elicits a significant behavioural placebo response. The observed differences 
could be attributed to a variety of factors. First of all, original brands generally enjoy 
greater credibility and trust. The price itself might be a factor that leads to higher 
expectations (Plassmann, O'Doherty et al. 2008, Plassmann and Weber 2015). Due 
to years of marketing, a trusted brand is associated with a higher price and better 
quality. The stronger placebo response in our study appears to be enhanced by the 
brand, which probably serves as an external cue, creating and reinforcing positive 
expectations towards the treatment. 
The active agent acetylsalicylic acid in Aspirin and its generics is generally used for 
treatment of headache pain. As pain trigger, we used heat induced pain applied with 
the Medoc System model ATS. Although this use is far from the regular use of ASA, 
we observed significant results on neuronal and behavioural levels. This 
observation emphasizes the expectations evoked by the branded placebo 
treatment. 
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During the native condition, before the administration of the placebo agent 
(comparison pain and no pain native), we observed higher activations of the anterior 
insula in the pain period compared to the baseline condition (no pain). The anterior 
insula is an essential brain structure for the sensation of pain and one of the 
classical pain processing areas (Brooks, Nurmikko et al. 2002). After the 
administration of the respective placebo (comparison before and after the 
intervention) we observed in both groups additional activations of the prefrontal 
cortex and of the cingulate gyrus, as well as higher activations of the bilateral 
insulae. These three areas are part of a brain network which is known to play a role 
in placebo analgesia (Elsenbruch, Kotsis et al. 2012). The activation of the opioid 
rich mPFC during the intervention condition may suggest an increased activity of 
the opioid system by the placebo treatment (Benedetti, Mayberg et al. 2005, Wager, 
Scott et al. 2007, Scott, Stohler et al. 2008, Wager and Fields 2013). 
During the anticipation phase only the generic group showed activations of the 
hippocampal areas. The hippocampus and its adjacent brain regions are involved in 
memory processes (Scoville and Milner 1957, Squire 1992). Patients with damages 
limited to the hippocampal areas showed memory impairment, particularly 
anterograde amnesia (Zola-Morgan, Squire et al. 1986). Due to its enormous neural 
connections, the hippocampus seems to have a very complex role in information 
processing, suggesting it to be an information integration unit consisting of several 
circuits and subunits (Moser and Moser 1998). The hippocampal areas are playing 
an essential role in memory formation, transforming newly gained memories into 
long-term memory (Huijgen and Samson 2015). Despite its role in memory 
processes, the hippocampus maintains close connections to the amygdala 
(Pitkänen, Pikkarainen et al. 2000) and seems to be involved in emotional 
evaluation and processing of emotional experiences. Increased pain reinforced by 
anxiety and therefore expectations of a negative outcome have been reportedly 
accompanied with activations in hippocampal areas suggesting a role in pain 
modulation processes (Ploghaus, Narain et al. 2001, Benedetti, Carlino et al. 2011). 
The nocebo response of hyperalgesia seems to be related to increased anxiety. In 
our study only participants in the generic group showed activations in the 
hippocampal areas during anticipation, suggesting anxiety and aversive emotions 
towards the treatment and therefore attributing negative expectations towards the 
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generic drug. These results are in line with higher anxiety levels in the generic 
group and also confirm results of Bingel et al. (2011), who investigated how different 
expectations influence the effectiveness of a potent pharmacological treatment with 
the µ-opioid receptor agonist remifentanil. The experiment consisted of three 
conditions: no expectations (hidden medication), positive expectations and negative 
expectations. Expectations of hyperalgesia (negative expectations) abolished the 
analgesic effect of remifentanil on a behavioural level. Furthermore, these negative 
expectations of treatment outcome were accompanied with additional increased 
activity in hippocampal areas, the mPFC and the cerebellum (Bingel, Wanigasekera 
et al. 2011). In accordance with our results, these findings support the idea that the 
hippocampal brain regions are involved in nocebo effects during opioid analgesia.  
The direct comparison between the two placebos during the intervention condition 
provided highly interesting results showing a significantly greater activation of the 
bilateral dmPFC and the bilateral dlPFC for the branded placebo condition. The 
opposite contrast (of the generic placebo compared to the branded placebo) did not 
show any significant activation. Several studies report the activation of the dmPFC 
in the context of negative affect suppression (Phan, Fitzgerald et al. 2005) as well 
as high level emotional appraisal and evaluation (Kalisch, Wiech et al. 2006). As 
pointed out in Chapter 1.2.4.4 the dlPFC has been repeatedly shown to be involved 
in expectation-related analgesia (Wager, Rilling et al. 2004, Zubieta, Bueller et al. 
2005, Krummenacher, Candia et al. 2010), suggesting that the branded placebo 
enhanced the participants’ expectations towards the effectiveness of the treatment, 
thus boosting the placebo response. The underlying mechanisms are not 
completely resolved, however, some authors assume a top-down effect of pain 
inhibition from the dlPFC (Lorenz, Minoshima et al. 2003). In a more general 
context, the dlPFC has been reportedly activated in processes of reasoning and 
decision making (Kable 2010, Kahnt, Heinzle et al. 2011).  
Positive expectations are an essential part of medical treatment and may enhance 
the analgesic placebo response. If a person attributes negative expectations to a 
treatment, the positive effect may be reversed resulting in hyperalgesia. In our 
study, we focused on the comparison between the treatment with an original and a 
generic brand. On the testing day, the participants were informed in writing that the 
Discussion 
 98 
generic drug contained the same active substance as Aspirin. Comparing the 
behavioural and neural results, the participants developed different expectations 
towards the treatment. The branded placebo triggered a stronger analgesic effect, 
possibly due to higher expectations and trust towards its effectiveness and reduced 
anxiety. 
In conclusion, our study enabled us to identify brain areas involved in the branded 
placebo response. The behavioural responses were consistent with these findings, 
showing a significant decrease in pain intensity for the branded group only. 
In addition to the behavioural level, results of the fMRI analysis revealed that the 
branded placebo elicited a significant analgesic response. The pattern of activated 
brain regions suggested that on a neuronal level, the processing of pain had been 
significantly modified. Thus, not only did the participants report increased pain 
reduction in the branded condition, but the modified analgesic response could also 
be displayed on a neuronal level. These results can demonstrate the potential 
consequences when changing a trusted medication to its generic equivalent. The 
trust and expectation towards a treatment, reinforced by a strong brand can have a 
major additional effect on the pain relief itself, which should not be underestimated. 
The participants received written information about the brand and the generic. 
Therefore, it has to be taken into consideration that information about painkillers can 
influence the sensation of pain. As demonstrated in our study, expectations can 
form an essential part of medical treatment and can have an impact on the clinical 
effectiveness even if no active agent is administered. The expectation towards a 
treatment is shaped by the brand. These expectations and attitudes are individually 
shaped by various factors such as a person’s emotional state and perspective. 
However, medical professionals can influence and control these psychological 
contexts to a certain degree to optimize expectations and thereby the total effect of 
treatment. It is evident, how significantly the passed-on information can influence 
drugs’ treatment efficacy as part of the patient communication. 
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6.  Appendices 
6.1. Selection Questionnaire 
1) Wie häufig verwenden Sie persönlich Schmerzmittel? Wir meinen hierbei frei 
verkäufliche Schmerzmittel, die man ohne Rezept in Apotheken erhält. 
o Seltener als 2 mal pro Monat 
o Mehr als 2 mal pro Monat 
o 1-2x pro Monat 
2) Welches frei verkäufliche Schmerzmittel haben Sie in den letzten 12 Monaten 
hauptsächlich verwendet? 
o Aspirin 
o Paracetamol 
o Ibuprofen 
o Andere 
3) Und welches frei verkäufliche Schmerzmittel haben Sie in den letzten 12 
Monaten hin und wieder auch verwendet? 
o Aspirin 
o Paracetamol 
o Ibuprofen 
o Andere 
4) Gegen Schmerzen werden häufig Tabletten auf Basis des Wirkstoffes 
Acetylsalicylsäure (ASS) genommen. Die bekannteste Marke darunter ist 
ASPIRIN von Bayer, dem Entdecker dieses Wirkstoffes. Es gibt heute aber auch 
andere Anbieter, die den Wirkstoff ASS verarbeiten, und sogenannte Generika 
anbieten (z.B. Hexal, Ratiopharm, 1A Pharma). Wie ist das bei Ihnen, welche 
Marke verwenden Sie? 
5) Viele Menschen vertrauen beim Einkauf bekannten Marken, die für Qualität 
stehen. Andere Menschen versuchen möglichst, ein günstiges markenfreies 
Produkt zu kaufen. Wie ist das bei Ihnen? 
o Ich kaufe meistens bekannte Marken 
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o Ich kaufe mal Markenprodukte, mal markenfreie Produkte 
o Ich kaufe fast nur markenfreie Produkte 
6) Ihr Geschlecht? 
o m 
o w 
7) Welche ist Ihre Muttersprache? 
8) In welchem Jahr sind Sie geboren? 
9) Welchen höchsten Bildungsabschluss haben Sie? 
o abgeschlossenes Studium 
o akademischer Titel 
o Haupt-/Volksschulabschluss 
o Realschulabschluss (mittlere Reife) oder gleichwertiger Abschluss 
o Schulreife 
10) Haben Sie eine Berufsausbildung im klinischen, pharmazeutischen oder 
medizinischen Kontext? 
o ja 
o nein 
11) Welcher Tätigkeitsstatus haben Sie derzeit inne? 
o teilweise berufstätig (halbtags oder stundenweise) 
o in Berufsausbildung (Schüler, Lehrling, Student) 
o voll berufstätig 
o vorübergehend arbeitslos 
12) Schlaganfall: Leiden Sie an folgenden Symptomen/Problemen? 
o ja 
o nein 
13) Epilepsie oder Anfälle: Leiden Sie an folgenden Symptomen/Problemen? 
o ja 
o nein 
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14) Drogensucht: Leiden Sie an folgenden Symptomen/Problemen? 
o ja 
o nein 
15) Alkoholismus: Leiden Sie an folgenden Symptomen/Problemen? 
o ja 
o nein 
16) psychische Erkrankungen: Leiden Sie an folgenden Symptomen/Problemen? 
o ja 
o nein 
17) Panikattaken: Leiden Sie an folgenden Symptomen/Problemen? 
o ja 
o nein 
18) Phobien: Leiden Sie an folgenden Symptomen/Problemen? 
o ja 
o nein 
19) Zwangsstörungen: Leiden Sie an folgenden Symptomen/Problemen? 
o ja 
o nein 
20) Platzangst: Leiden Sie an folgenden Symptomen/Problemen? 
o ja 
o nein 
21) neurologische/psychiatrische Vorerkrankungen: Leiden Sie an folgenden 
Symptomen/Problemen? 
o ja 
o nein 
22) Haben Sie einen Herzschrittmacher? 
o ja 
o nein 
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23) Haben Sie Metallimplantate (außer im Zahnbereich)? 
o ja 
o nein 
24) Haben Sie Sehhilfen (Brille oder Kontaktlinsen? 
o ja 
o nein 
25) Haben Sie Tätowierungen? 
o ja 
o nein 
26) Wenn Sie eine Tätowierung haben, bitte beschreiben Sie deren Größe und 
Position 
27) Nehmen Sie regelmäßig Medikamente? 
o ja 
o nein 
28) Wenn Sie regelmäßig Medikamente nehmen, welche sind dies? 
Welche Seite verwenden Sie überwiegend für die unten aufgeführten Tätigkeiten: 
Links/Rechts: Bitte versuchen Sie alle Fragen zu beantworten, und lassen sie eine 
Zeile nur dann leer, wenn sie überhaupt keine Erfahrung mit dem Objekt oder 
Aufgabe haben. 
29) Schreiben 
o links 
o rechts 
30) Malen 
o links 
o rechts 
31) Werfen 
o links 
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o rechts 
32) Schere 
o links 
o rechts 
33) Zahnbürste  
o links 
o rechts 
34) Messer 
o links 
o rechts 
35) Löffel 
o links 
o rechts 
36) Besen 
o links 
o rechts 
37) Streichholz zünden 
o links 
o rechts 
38) Schachtel öffnen 
o links 
o rechts 
39) Mit welchem Fuß treten Sie bevorzugt einen Gegenstand 
o links 
o rechts 
40) Welches Auge benutzen Sie, wenn Sie nur eines benutzen 
o links 
o rechts 
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6.2. Behavioral Questions Pain 
1) Nativ-Bedingung 1A 
a) Schmerzbewertung Durchgang 1A durchschnittlich: 
Wie bewerten Sie den Schmerzreiz auf einer Skala von 0-100 
durchschnittlich? 
b) Schmerzbewertung Durchgang 1A maximal: 
Wie bewerten Sie den maximalen Schmerzreiz auf einer Skala von 0-100? 
2) Nativ-Bedingung 1B 
a) Schmerzbewertung Durchgang 1B durchschnittlich: 
Wie bewerten Sie den Schmerzreiz auf einer Skala von 0-100 
durchschnittlich? 
b) Schmerzbewertung Durchgang 1B maximal: 
Wie bewerten Sie den maximalen Schmerzreiz auf einer Skala von 0-100? 
3) INTERVENTION 
a) Schmerzerwartung Durschnitt 
Welche Schmerzstärke erwarten Sie nach der Medikamentengabe im 
Durchschnitt 
b) Schmerzerwartung Durschnitt 
Welche Schmerzstärke erwarten Sie nach der Medikamentengabe Maximal 
4) Interventionsbedingung 2A 
a) Schmerzbewertung Durchgang 2A durchschnittlich: 
Wie bewerten Sie den Schmerzreiz auf einer Skala von 0-100 
durchschnittlich? 
b) Schmerzbewertung Durchgang 2A maximal: 
Wie bewerten Sie den maximalen Schmerzreiz auf einer Skala von 0-100? 
5) Interventionsbedingung 2B 
a) Schmerzbewertung Durchgang 2B durchschnittlich: 
Wie bewerten Sie den Schmerzreiz auf einer Skala von 0-100 
durchschnittlich? 
b) Schmerzbewertung Durchgang 2B maximal: 
Wie bewerten Sie den maximalen Schmerzreiz auf einer Skala von 0-100? 
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